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ABSTRACT
The extracellular matrix (ECM) has been shown to be a significant source of hindrance to
the transport of macromolecules in solid tumors. This thesis shows that by limiting their
interstitial transport, the tumor ECM can reduce the efficacy of cancer therapeutics.
Furthermore, techniques for overcoming this transport barrier and improving the
effectiveness of existing cancer therapetuics are developed. Mathematical modeling was
utilized to characterize the distribution of a therapeutic herpes simplex virus (HSV)
vector in solid tumors. The model showed that the spread of virus following intratumoral
injection is severely limited by rapid binding and limited diffusion. Importantly, the
model demonstrates that an improvement in virus diffusion can enhance its distribution
significantly. In vivo multiphoton imaging of fibrillar collagen type I and injected HSV
vectors largely supported the model predictions. Injected viral particles could not
penetrate dense networks of fibrillar collagen. Both the initial distribution and subsequent
propagation of these replication-competent vectors were limited by collagen. Degradation
of tumor collagen with bacterial collagenase enhanced the distribution and efficacy of the
virus. To develop a technique that is clinically applicable, human collagenases were
screened for similar activity. Matrix metalloproteinase (MMP) -1 and -8 were identified
as viable candidates and tested for their ability to degrade collagen and enhance diffusion
in tumors. When overexpressed in tumors, neither MMP significantly altered collagen
content or diffusive transport. However, these MMPs have multiple matrix substrates and
were found to deplete the tumor of sulfated glycosaminoglycans (GAGs). This, in turn,
increased the hydraulic conductivity of these tumors, enhancing the distribution and
efficacy of infused oncolytic HSV. Genetic mutations were employed to enhance the
activity of these enzymes, but impaired intracellular processing and inactivating
autoproteolytic degradation reduced overall activity. Thus, our work demonstrates the
importance of the tumor extracellular matrix in regulating the distribution and efficacy of
cancer therapeutics. Methods to modulate both tumor collagen and sulfated GAGs are
developed to enhance interstitial transport and improve the treatment of solid tumors.
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Chapter 1: Background and Specific Aims
Introduction
Cancer is the second leading cause of death in the U.S., accounting for nearly a quarter of
all deaths in 2004. The American Cancer Society estimates that 559,650 Americans will
die from cancer this year and over 1.4 million new cases will be diagnosed (1). More than
85% of cancer patients have solid tumors. Traditionally, chemotherapeutics have been
used in combination with surgery and radiation to treat solid tumors. However, systemic
treatment with these non-specific chemical agents frequently causes considerable
morbidity. Novel therapeutics such as antibodies and viral vectors have recently been
developed to provide more targeted treatment. However, these therapeutics face transport
barriers not experienced by small molecule chemotherapeutics due to their larger size and
unique physicochemical properties.
In order for a cancer therapeutic to be effective, sufficient amounts must be delivered to
its target, often the cancer cells. There are various mass transfer barriers associated with
delivery of targeted therapeutics to tumor cells (2, 3). A therapeutic agent injected
intravenously first must distribute throughout the tumor microvascular space and
extravasate across the microvessel wall. Alternatively, these steps can be overcome by
direct injection into the tumor. However, the transport of intratumorally infused
therapeutics can be limited by extracellular matrix components. Fibrillar collagens may
impede uniform distribution by acting as structural barriers and glycosaminoglycans can
hinder fluid flow during infusion (4, 5).
Therapeutics delivered both locally and systemically then face barriers to transport in the
interstitial space of the tumor. Except in the tumor margin, interstitial transport is
meditated mainly by diffusion and not convection, a consequence of the uniformly high
interstitial fluid pressure within tumors (6, 7). While diffusion is relatively rapid for small
molecule chemotherapeutics, it can be a slow process for novel targeted therapeutics
which can be orders of magnitude larger. Hindered diffusion may limit the distribution
and thus effectiveness of these therapeutics. Fibrillar collagen I is one of the primary
constituents of the tumor extracellular matrix (ECM) and collagen I content and structure
have been correlated with limited diffusion (8-12). Modulating the tumor extracellular
matrix to improve the transport of therapeutics during and after intratumoral infusion is
the focus of this thesis.
Specific Aims
Hypothesis: Delivery of a matrix-modulating enzyme to the tumor interstitium can
improve the interstitial transport, distribution and efficacy of a macromolecular
cancer therapeutic.
Specific Aim 1: Develop a mathematical model to characterize the relative effect of
binding and diffusion on the distribution of a herpes simplex virus (HSV) vector in solid
tumors.
A mathematical model has yet to be developed to describe the relative role of binding and
diffusion on the distribution of HSV vectors in a solid tumor. Such a model will provide
us with a greater understanding of the physical underpinnings governing the distribution
of therapeutic viruses in tumors. Furthermore, it would provide us with an estimate of the
effect that improvements in diffusion would have on intratumor virus distribution, as well
as provide other targets for improving viral delivery.
Specific Aim la: Perform in vitro experiments to determine rate constants for binding
and degradation.
The rate constant for HSV binding to its cell surface receptor will be determined in vitro
for human cancer cells. Virus will be incubated with cells and the concentration of virus
remaining in the supernatant will be monitored over time. To determine the rate of
degradation, virus will be incubated with tumor cell conditioned media and the
concentration monitored over time.
Specific Aim lb: Develop a 1D model incorporating virus binding, diffusion and
degradation and analyze their relative roles in virus distribution.
Parameters obtained in Aim 1 a and from the literature will be used to generate a 1 D
model of virus distribution in a solid tumor. The scenario of direct intratumor injection of
the virus into the center of the tumor will be modeled to reflect experimental conditions.
The relative effects of binding, diffusion and degradation on virus distribution will be
assessed. A sensitivity analysis will be performed to determine how changes in tumor and
virus parameters affect the distribution of virus in the tumor.
Specific Aim 2: Determine the effect of bacterial collagenase on the distribution and
efficacy of an oncolytic HSV vector.
Fibrillar collagen has been shown to be the cause of severe diffusional hindrance of tracer
molecules in tumors and bacterial collagenase has been used to degrade collagen and
increase the diffusion coefficient of these tracers. This study intends to show that these
findings have relevance to cancer therapy by providing evidence that (1) fibrillar collagen
limits the effectiveness of a macromolecular cancer therapeutic by hindering its
interstitial transport and (2) bacterial collagenase can be used to enhance therapeutic
efficacy.
Specific Aim 2a: Determine how fibrillar collagen affects the distribution and efficacy of
intratumorally injected HSV vectors.
Human tumors will be grown in the dorsal skinfold chamber of mice and EGFP-labeled
HSV vectors will be injected intratumorally. Fibrillar collagen (second harmonic
generation (SHG)) and virus (EGFP) will be imaged simultaneously multiphoton
microscopy following injection. The effect of fibrillar collagen on virus distribution will
be quantified by image analysis. Fluorescently-labeled tracer molecules of different sizes
will be injected for comparison. For oncolytic viruses, imaging will be performed up to
two weeks following injection to observe virus replication and spread.
Specific Aim 2b: Assess the effect of bacterial collagenase on the distribution of
intratumorally injected HSV vectors.
Tumors will be injected with virus in combination with bacterial collagenase and imaged
as before. The effect of bacterial collagenase on initial virus distribution and subsequent
spread throughout the tumor will be assessed by image analysis.
Specific Aim 2c: Determine if bacterial collagenase can enhance the efficacy of
intratumorally injected oncolytic HSV vectors.
Tumors will be grown subcutaneously in the flank of mice. They will be treated with two
injections of either PBS, bacterial collagenase, oncolytic virus or oncolytic virus in
combination with bacterial collagenase. Tumor size will be measured following treatment
and the delay in tumor growth compared for different treatments. The effect of bacterial
collagenase on metastasis will also be assessed.
Specific Aim 3: Determine the effect of acute delivery of recombinant human
collagenases on tumor collagen, interstitial diffusion and the efficacy of oncolytic HSV
therapy.
In order to apply the matrix modifying technique clinically, human collagenases must
ultimately be used. Here we screen various human collagenases for their ability to
degrade collagen in vivo and improve the transport and efficacy of a therapeutic. As in
Aim 2, recombinant collagenases will be applied directly to tumors.
Specific Aim 3a: Screen human collagenases for the ability to degrade collagen in vitro
and in vivo.
Various human collagenases will be screened for their ability to degrade fibrillar type I
collagen in an in vitro assay. Promising candidates will be tested in vivo. Recombinant
human collagenase will be superfused onto the surface of tumors grown in the dorsal
chamber. SHG imaging will be performed at various time points after superfusion and the
total collagen content quantified by image analysis.
Specific Aim 3b: Determine the effect of recombinant human collagenases on interstitial
diffusion.
Recombinant human collagenase will be superfused onto the surface of tumors grown in
the dorsal chamber. At an appropriate time point following treatment (determined in Aim
3a), a fluorescently-labeled tracer molecule will be intratumorally injected. The diffusion
coefficient of the tracer will be measured with fluorescence recovery after
photobleaching (FRAP) and compared for different treatments.
Specific Aim 3c: Determine the effect of recombinant human collagenases on the efficacy
of oncolytic HSV therapy.
Tumors will be grown subcutaneously in the leg of mice. At a given size, tumors will be
treated with an intratumor injection of either PBS, oncolytic virus alone or virus in
combination with a recombinant human collagenase. Tumor volume will be measured
every several days following treatment and the tumor growth delay compared.
Specific Aim 4: Determine the effect of chronic delivery ofMMP-1 and -8 on the tumor
extracellular matrix, interstitial transport and the efficacy of oncolytic HSV therapy.
An alternative approach to delivering a collagenase to the tumor as a recombinant protein
is to express it in tumor cells. In practice, this can be achieved either by expressing
collagenase in tumor cells by stable transfection or by incorporating the collagenase gene
in the viral genome of the oncolytic vector. One advantage to this method is that the
collagenase is delivered chronically to the tumor, increasing the effective dose. We will
develop tumors and oncolytic viruses which express MMP-1 and MMP-8 (both found in
Aim 3a to be suitable enzymes). As these enzymes can degrade multiple ECM substrates,
the effect on collagen and other matrix components will be determined. Since chronic
expression of these enzymes may have profound effects on the structure and composition
of the tumor matrix, the effect on both diffusive and convective transport will be assessed
Specific Aim 4a: Generate tumors overexpressing MMP-1 and -8.
Tumor cells will be stably transfected with each MMP. MMP-expressing tumors will be
grown subcutaneously in the flank of mice. Tumors will be harvested and western blot
performed to confirm collagenase expression in vivo.
Specific Aim 4b: Determine the effect ofMMP-1 and -8 overexpression on tumor
extracellular matrix content.
MMP-expressing tumors will be grown in the dorsal chamber. When the tumors reach a
given size, SHG imaging will be performed and total collagen content will be quantified
by image analysis. Additionally, collagen and hyaluronic acid (HA) content will be
assessed with immunohistochemistry. MMP-expressing tumors will be grown
subcutaneously in the flank of mice. Tumors will be harvested, fixed and immunostained
for type I collagen and HA. Stained sections will be imaged and analysis performed to
determine the total collagen and HA content. The sulfated glycosaminoglycan (GAG)
content will be determined with a biochemical assay.
Specific Aim 4c: Determine the effect ofMMP-1 and -8 overexpression on tumor
interstitial transport.
MMP-expressing tumors will be grown in the dorsal chamber. When the tumors reach a
given size, a fluorescently-labeled tracer molecule will be intratumorally injected. The
diffusion coefficient of the tracer will be measured with FRAP and compared for
different collagenases. Hydraulic conductivity will be determined in each tumor type by
measuring the rate of fluid flow through tissue sections under an applied pressure
gradient.
Specific Aim 4d: Determine the effect of MMP-1 and -8 overexpression on the efficacy of
oncolytic HSV therapy.
MMP-expressing tumors will be grown subcutaneously in the leg of mice. For each
MMP-expressing and control tumor, the following growth delay assay will be performed.
At a given size, tumors will be treated with an intratumor injection of either PBS or
oncolytic virus. Tumor volume will be measured every several days following treatment.
The growth delay induced by oncolytic HSV treatment will be compared between MMP-
expressing and control tumors. If appropriate, histological analysis will performed to
determine the distribution of HSV particles in each tumor type.
Specific Aim 4e: Generate recombinant oncolytic HSV vectors which express MMP-1 and
-8 and determine the effect on therapeutic efficacy.
MMP-expressing oncolytic HSV vectors will be generated using homologous
recombination. The MMP-1 and -8 expression cassettes will be inserted in the ICP6 locus
of the HSV genome. MMP expression will be confirmed by western blot of tumor cells
infected in culture. Wild type tumors will be grown subcutaneously in the flank of mice
and will be treated with intratumor injections of each recombinant oncolytic HSV vector.
Tumor volume will be measured and the effect of MMP expression on growth delay
assessed.
Specific Aim 5: Generate constitutively active forms ofMMPs to enhance ECM
modulation in vivo.
Human collagenases of the MMP family are secreted as inactive zymogens that require
cleavage of their propeptide domains to become activate. Thus, insufficient activation in
the interstitial space (due to lack of appropriate proteases) may limit the collagen
degradation achieved. In this aim, truncated forms of MMPs are developed to bypass this
activation step and augment collagen degradation in tumors.
Specific Aim 5a: Generate truncated forms of each MMP which lack the propeptide
domain and test the ability of these truncated proteins to degrade fibrillar collagen.
Truncated forms of each MMP will be generated by PCR and subcloned into an
appropriate expression vector. 293ET cells will be transiently transfected and western
blots performed on the conditioned media to confirm expression and secretion of the
truncated MMP. An in vitro collagenase assay will be used to assess the activity relative
to the wild type enzymes.
Specific Aim 5b: Generate forms of each truncated MMP which contain stabilizing
mutations in the hinge region and test for the ability of these mutants to degrade fibrillar
collagen.
Active forms of MMPs may go through inactivating autoproteolytic degradation. The site
of intramolecular cleavage in is the hinge domain. Site-directed mutagenesis will be
performed on the truncated forms of each MMP (generated in Aim 5a) to stabilize the
recombinant enzymes. Mutations will be generated by PCR. 293ET cells will be
transiently transfected and western blots performed on the conditioned media to confirm
expression and secretion of the mutated MMPs. An in vitro collagenase assay will be
used to assess the activity relative to the truncated and wild type enzymes.
Background
Composition of tumor extracellular matrix
Solid tumors consist of two interconnected compartments: the malignant cells and the
stroma in which they are dispersed. Stroma is induced by tumor-host interactions and is
required for tumor growth and survival (13). It consists mainly of interstitial connective
tissue but also includes the blood vessels that provide the tumor cells with nutrients and
allow for gas exchange and waste disposal. The major components include leaked
plasma; proteoglycans (PGs) and glycosaminoglycans (GAGs); interstitial collagens
(types I, III, and V); fibrin; fibronectin; connective tissue cells such as fibroblasts; and
inflammatory cells (13).
Tumor stroma generation is attributed to the hyperpermeability of the tumor vasculature
(14). Plasma proteins, particularly fibrinogen and other clotting factors, extravasate and
rapidly clot, forming a gel of crosslinked fibrin (15). This provisional matrix entraps
extravasated plasma proteins and water. Furthermore, it stimulates the inward invasion of
endothelial cells and fibroblasts (16, 17), which results in the transformation of the
provisional matrix into a more highly cellular and vascular matrix (15). Structural
proteins such as interstitial collagens are synthesized, resulting in the mature collagenous
stroma.
Collagen type I is the major fibrous protein in the interstitial matrix and is produced by
host stromal cells in most tumors (15, 18). The type I collagen monomer is a 300 nm
long, 1.5 nm diameter protein consisting of three subunits, two aI chains and one all
chain, associated in a right-handed triple helix. Procollagen is discharged vectorially into
extracellular compartments to promote fibril formation in a desired location (19). N- and
C- proteinases cleave the propeptide segments forming tropocollagen (also called
collagen); this process leads to the formation of stable fibrils (20). Fibril diameters range
from 50-200 nm and lengths are up to several micrometers. Fibril assembly occurs in
fibril forming compartments and fusion of these narrow compartments can lead to the
formation of fibers (21, 22).
The tumor interstitial matrix contains several other components besides collagen. The
other major components of the tumor interstitial matrix include: hyaluronic acid (HA);
sulfated GAGs, which bind to PG core proteins; and fibronectin, which allows cells to
bind collagen via cell surface integrins (23). The hydrated gel of HA, together with
collagen, provides structural integrity to the matrix and resistance to compressive forces
(24, 25). PGs such as decorin and versican function to organize the matrix by binding to
collagen and HA, respectively (26). The interstitial matrix can be quite variable from one
tumor to another: while some have very little matrix material, others, such as
desmoplastic carcinomas of the breast and colon, generate excessive amounts of fibrillar
collagen and elastin that separate the tumor nodules (27, 28). In general, tumors contain
higher levels of GAGs and PGs than normal tissues (29, 30) and the PGs tend to be larger
and have longer GAG side chains (31, 32).
Tumor interstitial transport
This thesis focuses on the last mass transfer barrier for therapeutics targeted for cancer
cells: transport through the interstitial space. Therapeutics that have either transported
across the microvascular wall or have been injected directly into the tumor distribute in
the interstitium via convection and diffusion. However, it has been found that molecular
therapeutics do not distribute uniformly in tumors, with low concentrations reaching
tumor cells distant from the vasculature (33-37). There are two major reasons for this.
First, interstitial fluid pressure (IFP) is uniformly elevated in solid tumors, dropping to
lower levels only in the tumor periphery and surrounding tissue (38). This is caused by
both the increased permeability of blood vessels (39) and the lack of functional
intratumor lymphatics (6, 7), which lead to an accumulation of fluid in the tumor
interstitium. As a result there are almost no pressure gradients between the vasculature
and surrounding tissue and convection is negligible except at the tumor periphery (38, 40,
41). Interstitial transport of molecular therapeutics is therefore governed mainly by
diffusion. This is a much slower process, especially for large therapeutics such as
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Figure 1.1. Size distribution of cancer therapeutic agents. While conventional
chemotherapeutics are generally less than a nanometer in diameter, antibodies are an
order of magnitude larger and viruses and liposomes are two to three orders of
magnitude larger.
The second factor contributing to poor interstitial transport is the ECM - composed of
collagen, proteoglycans and glycoproteins - which provides resistance to fluid and solute
movement (42-44). The diffusion of solutes is considerably slower through connective
tissue than water (45). Fluid flow has also been shown to be hindered by GAGs in tissue
(4, 5). Measurements of the hydraulic conductivity of a variety of tissues has established
a negative monotonic relationship with total GAG content (43, 46). Degradation of the
non-sulfated GAG HA with hyaluronidase has been shown to increase hydraulic
conductivity in several tissues (4, 47). The sulfated GAGs have been implicated, as well.
The application of trypsin to deplete corneal stroma of sulfated GAGs resulted in a
greater increase in hydraulic conductivity than with hyaluronidase (47).
Based on these findings, resistance to fluid flow and diffusion has been traditionally
linked to GAGs. It was thought that fibrillar components such as collagen and elastin
have little influence since they form large pore networks. However, this interpretation
was challenged by the observation that tissue permeability is significantly lower than
measurements made in vitro with GAG networks of similar concentration. Subsequent
studies have shown that, indeed, matrix factors other than GAGs cannot be ignored in the
analysis of interstitial transport (43, 44, 48). Levick observed that fibrillar components
such as collagen may significantly influence transport in tissue because of hydrodynamic
drag and the tortuous nature of the flow path, as well as by affecting the distribution and
effective concentration of GAGs (43).
Tumor tissue may exhibit distinctive interstitial transport characteristics since tumor
progression involves a wound healing-like stage with extensive synthesis of ECM
constituents (14, 18, 30). The composition of the tumor interstitial matrix differs in both
composition and structure from that of the host and varies from one type to another (30,
49). The unique nature of the tumor interstitial matrix merits a specific study of tumor
tissue to determine the relative roles of various ECM components as barriers to diffusive
transport. The method used to measure diffusion coefficients has been fluorescence
recovery after photobleaching (FRAP) (50, 51). In this method, the effective diffusion
coefficient of a fluorescently-labeled tracer is measured by creating a photobleached
pattern with a laser and performing image analysis on the diffusion-mediated recovery of
the photobleached area. FRAP has been used to study diffusive transport in gels (12),
spheroids (9) and in vivo tumor tissue (10, 11, 51).
Netti et al. (10) measured the diffusion coefficient ofIgG in several tumors in vivo and
found that it correlated with collagen, but not GAG or HA, content. Histological data
showed that tumors with a low IgG diffusion coefficient had a well organized collagen
network compared to other tumors. Pluen et al. (11) subsequently measured the diffusion
coefficient of various probes in two tumor models (host sites): the dorsal chamber and
cranial window. As expected, they found that the effective diffusion coefficient varied
inversely with molecular hydrodynamic radius. Furthermore, they observed that the large
macromolecules (IgG, IgM, dextran 2,000,000 MW) diffused much faster in tumors
grown in the cranial window compared to the dorsal chamber for the same tumor type. In
agreement with the study of Netti et al., immunohistochemistry showed that dorsal
chamber tumors exhibit abundant fibrillar collagen type I while cranial window tumors
showed only sparse collagen. These studies suggested that tumor collagen composition
and organization significantly affect the penetration of macromolecules.
Further evidence that implicated tumor fibrillar collagen in diffusive hindrance was
obtained from an in vitro collagen gel study (12). Collagen gels were prepared at
concentrations similar to that found in various solid tumors and the diffusion coefficient
of a range of tracers was measured by photobleaching. When the diffusion coefficients
were adjusted to account for the tortuosity of the tumor interstitial space, they closely
matched the diffusion coefficients in tumors of comparable collagen content. This study
suggested that collagen can account for most of the diffusional hindrance in tumors. In
total, these interstitial diffusion studies provide evidence that collagen content and
structure play a significant role in regulating tumor interstitial diffusion and show that
collagen fibers are excellent targets for matrix modification for improved transport.
Matrix modification to improve interstitial diffusion
To validate that collagen plays a key role in diffusive hindrance and to provide proof of
principle that its modification can be used to improve interstitial transport, the diffusion
coefficient of tracer molecules has been measured following application of various ECM
degrading factors. First, dorsal chamber tumors were treated with either bacterial
collagenase or hyaluronidase to assess their ability to alter interstitial diffusion (10).
While bacterial collagenase treatment increased the diffusion coefficient ofIgG by
approximately two-fold in two tumor types, hyaluronidase had no effect.
Alexandrakis et al. (52) developed a method for measuring diffusion coefficients in vivo
using fluorescence correlation spectroscopy (FCS) with a multiphoton microscope. This
method has further shed light on the effect of matrix modification on interstitial diffusion.
In the FCS experiment, the fluctuations in fluorescence intensity detected in the two-
photon focal volume - a result of the random movement of fluorescent particles in and
out of the volume - are used to extract information about the diffusion of the molecules
(53, 54). FCS measurements revealed both fast and slow diffusing components for a
tracer injected into tumors, although this tracer exhibited only a single diffusion
coefficient in free solution. This result provided evidence of the two-phase nature of
diffusion in the tumor interstitium. Application ofhyaluronidase to tumors decreased the
fraction of rapidly diffusing molecules and decreased the diffusion coefficient of the slow
diffusing molecules. Bacterial collagenase treatment increased the proportion of the fast
diffusion component while not altering the diffusion coefficient of either component.
Recently, Brown et al. developed the novel technique of second harmonic generation
(SHG) imaging to dynamically image and quantify fibrillar collagen in vivo (8). They
used it to characterize changes in collagen induced by the treatment of tumors with the
peptide relaxin and correlated these changes in collagen to interstitial diffusion. SHG is a
scattering phenomenon exhibited by various anisotropic materials and has been shown to
be induced by collagen (55-57). Relaxin is a peptide hormone produced mainly in tissues
of the reproductive system and has been shown to have the ability to remodel the ECM
(58-60). Relaxin can modify the matrix through several processes. Relaxin decreases the
synthesis and secretion of collagen I molecules in various in vitro models (61, 62) and
has also shown to have the ability to increase the expression of various matrix degrading
molecules (61, 63-66). Brown et al. found that chronic treatment of a fibrous sarcoma
with relaxin increased collagen turnover: while total SHG signal did not change over
time, the length of existing fibers decreased. These changes led to -50% and 100%
increases in the diffusion coefficients of IgG and 2x10 6 molecular weight dextran,
respectively.
These studies further support the hypothesis that interstitial fibrillar collagen is
responsible for the limited diffusion of large macromolecules in fibrous tumors.
Furthermore, they demonstrate that collagen degradation can be used as a technique to
improve diffusive transport in tumors. This thesis aims to expand on these findings in two
respects: (1) show that improved diffusion can be extended to therapeutics and will lead
to improved efficacy of cancer treatment; (2) develop clinically relevant methods to
degrade tumor fibrillar collagen by testing various human collagenases.
Matrix metalloproteinases (MMPs)
The human matrix metalloproteinases (MMPs) are a family of endopeptidases that can
cleave nearly all ECM components, as well as other non-matrix proteins and cell surface
molecules (67-69). They are involved in both normal tissue remodeling during
development and maintenance, as well as in various diseases involving fibrosis or
excessive tissue destruction. The MMP family includes both membrane-bound and free
enzymes, and all bind Zn2+ at the catalytic site. Three of the secreted MMPs are capable
of cleaving collagen type I: MMP-1 (interstitial collagenase, collagenase-1) (70, 71),
MMP-8 (neutrophil collagenase, collagenase-2) (72) and MMP-13 (collagenase-3) (73).
The collagenases share a similar domain structure, consisting of an N-terminal signal
peptide, propeptide domain, catalytic domain, hinge region and C-terminal hemopexin-
like domain. The propeptide domain functions to keep the MMP in a latent zymogen
form: a cysteine sulfhydryl group in this domain acts as a fourth ligand for the catalytic
site zinc and must be removed to allow a water molecule to bind and cleave peptide
bonds of MMP substrates (74, 75). Activation occurs extracellularly and begins with
truncation of the propeptide domain, either autoproteolytically or by other MMPs and
proteases, followed by removal of the remaining propeptide fragment by the truncated
zymogen, itself, to form the mature enzyme (76). The collagenases all cleave the
individual chains of the triple-helical collagen I molecule at a specific peptide location,
Gly775-Leu/Ile776 (77-79), and appear to cleave all three chains together, with no
preference for individual chains (76). The collagenase activity of these MMPs is inhibited
by the secreted proteins tissue inhibitors of MMP (TIMPs) 1-4 in a stoichiometric fashion
(79-84). It should be noted that while these MMPs are primarily characterized as type I
collagenases, they are also able to cleave other extracellular matrix components including
proteoglycans, glycoproteins and other fibrillar collagens (69).
With their ability to degrade nearly all ECM components and many cell surface proteins
the MMPs have been implicated in various processes of cancer progression. Notably,
certain MMPs have been found at elevated levels in various cancers and have been linked
to the increased invasiveness and metastatic potential of cancer cells (85). They are
involved in several processes of metastasis, including migration through the tumor
stroma, invasion across the basement membrane and entrance into and extravasation from
blood vessels or lymphatics. Important to this work, MMP-1, -8 and -13 show elevated
expression in various cancers relative to surrounding non-neoplastic tissue (86-91) and
have been correlated with increased invasiveness and metastatic potential (87, 89, 92-94).
However, little evidence exists that these collagenases are directly involved in the
metastatic process. In fact, there is emerging evidence that MMP-8 may play an anti-
metastatic role (95, 96).
Oncolytic viruses
Oncolytic viral therapy is the use of a replication competent virus to selectively kill
cancer cells (Fig. 1.2). Antitumor efficacy is generally mediated by cell lysis or
cytotoxicity of viral proteins, but can also arise from the induction of an immune
response or expression of a cytotoxic transgene (97). The are generally two methods to
generate tumor cell selectivity: selective infection and selective replication (98). To
achieve tumor-selective infection, the surface of viral particles can be engineered to
display proteins which bind specifically to receptors on the surface of tumor cells. Tumor
cell selective replication is generally attained by either placing essential viral genes under
the control of a tumor-specific promoter or by mutating or deleting viral genes that are
are essential to viral replication in normal cells, but non-essential in neoplastic cells. The
two most extensively investigated viruses for oncolytic therapy are adenovirus and HSV
(98-100).
HSV is an enveloped, double stranded DNA virus which is non-integrating. Oncolytic
HSV vectors have been developed both by incorporating tissue-specific promoters (101)
and through the use of deletion mutations to inactivate proteins required for viral
replication in normal cells (102). First generation deletion mutants focused on enzymes
involved in nucleotide metabolism (such as ribonucleotide reductase (103, 104) and
thymidine kinase (102, 105)) or the neurovirulence factor y34.5 (106, 107). These vectors
provided proof of principle that safe and effective replication-competent HSV-1 vectors








Figure 1.2. Oncolytic virus mechanism of action. The schematic shows the life cycle
of a recombinant, oncolytic vector which has been mutated such that it selectively
replicates in tumor cells but not normal cells. An oncolytic virus can infect a normal
cell (blue) but will not be able to produce progeny virus. Conversely, when an
oncolytic virus infects a tumor cell (purple), productive replication of progeny virus
will occur. Infected cells will be lysed and progeny virus can go on to infect






mutations to balance safety and efficacy. The multimutated vector G207 (MGH1)
incorporates deletions of both copies of y34.5 and the inactivating insertion of the E. coli
LacZ gene into the ribonucleotide reductase gene ICP6 (108, 109). Recently, other HSV-
1 vectors have been developed based on the same strategy. MGH2 is identical to MGH1
except that the LacZ insertion is replaced by the insertion of a transcription cassette
containing the gene for enhanced green fluorescent protein (EGFP) and the prodrug
activating genes CYP2B1 and secreted human intestinal carboxylesterase (110). Terada et
al. developed a method to generate HSV-1 vectors similar to G207/MGH1 but with the
insertion of EGFP and any gene of interest (instead of LacZ) in ICP6 (111).
G207 has been shown to be quite potent and safe in preclinical studies (109, 112-114).
While developed for brain tumors, it has also been effective for other solid tumors
including melanoma, breast and liver (115). The combined treatment of G207 and the
chemotherapeutic cisplatin was effective for the treatment of head and neck squamous
cell carcinoma in an animal model (116). Based on these encouraging preclinical
findings, a phase I clinical trial was conducted with 21 glioma patients (117). All of the
patients tolerated the treatment and showed no serious adverse effects. Eight patients
showed reduction in tumor volume from 4 days to 1 month after treatment. G207 is
currently in a phase I clinical trial of malignant brain tumors.
Although recent clinical trials have demonstrated the potential of adenovirus and HSV as
oncolytic vectors in cancer therapy (118), the issue of poor distribution throughout the
tumor remains (35, 119). As evidence of this, multiple injections with fractionation of the
dose is often used to improve intratumor delivery, albeit with limited gains (120). While
vector distribution is often acknowledged as a significant factor in determining overall
treatment efficacy, few studies specifically address this issue. This thesis examines the
possibility of improving the transport and effectiveness of such vectors through
modulation of the tumor extracellular matrix.
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Chapter 2: Modeling of Herpes Simplex Virus Distribution in a
Solid Tumor
Portions of the chapter have been taken from:
W. Mok and R.K. Jain, "Modeling of Herpes Simplex Virus Distribution in Solid Tumors:
Implications for Cancer Therapy." In submission
Introduction
Viral vectors offer a promising approach to cancer treatment. Methods of antitumor
efficacy can include cell lysis, cytotoxicity of viral proteins, induction of an immune
response and expression of a cytotoxic transgene (1, 2). Oncolytic viral therapy -
treatment with viruses that have been genetically modified to selectively replicate in
cancer cells but not non-neoplastic cells - is a rapidly developing cancer gene therapy
platform that can exhibit each of these anti-tumor properties (3, 4). Two of the most
actively investigated viruses, adenovirus and herpes simplex virus (HSV), have
demonstrated systemic safety and efficacy in various clinical applications (5, 6).
While viral gene therapy vectors show remarkable biological specificity and activity for
the treatment of solid tumors, they suffer in comparison to conventional
chemotherapeutics in one main respect: intratumor distribution. Viruses are orders of
magnitude larger than small molecule chemotherapeutics (< 1 nm vs 50-200 nm) and
encounter severe transport limitations in the tumor interstitium. The limited penetration
of large vectors from the injection site or the vasculature has been well documented (7-9).
The tumor extracellular matrix most likely plays an important role in the distribution of
viral vectors within tumors (10, 11). In order to properly assess the therapeutic potential
of a viral cancer gene therapy vector - as well as devise optimal delivery methods - a
detailed understanding of the root causes of limited vector distribution is needed.
Mathematical modeling offers a useful method to explore this issue and guide
experimental strategies to improve viral vector distribution and thus efficacy. Several
models of oncolytic viral therapy exist in the literature (12-14). While highly informative,
these models focus on the role of various biological processes such as the immune
response and the cytotoxicity, infectivity and burst size of the virus. In addition, they
compare how different treatment/delivery schemes - manifested as initial intratumor viral
distribution - affect the ability to control tumor growth with oncolytic viral therapy. The
present investigation aims to address the more fundamental questions of how these initial
distributions arise and what physicochemical characteristics of the virus are responsible.
We consider the role of viral binding, diffusion and degradation and explore the potential
improvements in distribution with various modifications to both the virus and tumor.
Furthermore, while the previous models describe the behavior of adenoviral vectors, this
study focuses on HSV, which also shows great potential in tumor treatment.
Experiments are performed in this study to determine the rate constants for viral
degradation (via hydrolysis) and cell surface binding and the concentration of heparan
sulfate on the surface of tumor cells. Values for the volume and concentration of virus
following intratumor infusion and the effective diffusion coefficient of viral particles in
the tumor are estimated from our previous work (10, 15) and work described in Chapter
3. Other parameters have been estimated from the literature. The model shows that
intratumorally infused virus will spread minimally from the site of injection, a
consequence of rapid cell surface binding and limited diffusion. However, various
modifications to the tumor and virus can markedly improve the distribution of virus in the
tumor.
Model Development
The tumor is modeled as a sphere of radius R. Diffusion-reaction equations describe the
interstitial concentration of virus as a function of time and radial position. Diffusion in
the interstitial compartment, binding of HSV particles to cells and degradation of both
free and bound viral particles via hydrolysis are the processes described (Fig 2.1). Two





Figure 2.1. Schematic diagram of model. The tumor is modeled as a sphere. Initially
virus is uniformly distributed in a spherical volume at the center of the tumor. Over
time, virus spreads into the adjacent space. Three processes are considered: (1)
association and dissociation of virus and cell surface heparan sulfate; (2) degradation of
free and bound virus; (3) diffusion of free virus. At baseline conditions, HSV particles
spread minimally from the initial injection volume due to rapid binding and slow
diffusion. However, the spread of virus into the adjacent space can be enhanced by
--- - o
HSV binding to the cell surfaces and subsequent internalization is not mediated by a
simple single ligand-single receptor interaction. Rather it is a multi-step process which
involves several viral envelope glycoproteins (16). Thus assumptions were made to
facilitate mathematical modeling. Cell surface binding has been found to be primarily
mediated by the interaction of the viral glycoproteins gB and gC with heparan sulfate
(17-19). A comparison of binding affinities (20, 21) and separate mutant virion analyses
(22, 23) suggest that gC binding to heparan sulfate is the primary mechanism for cell
surface attachment of HSV. Thus we have modeled the binding of HSV to cells as an
interaction between the glycoprotein gC and cell surface heparan sulfate. A second
ligand-receptor interaction (gD-HVEM) facilitates internalization. Because the details of
internalization are not well-understood, the internalization process was not included in
the present model.
The concentration profile for free (interstitial) virus and bound virus are given by
ac, _ D r (r2 aC, _ konC,(CH -aCB) kC -kdC I  (1)
at r2 ar or )
aCB koC, (CH - aC,)Sk C,-dB (2)8t
either decreasing the binding affinity of HSV for heparan sulfate (e.g. via modifications
to viral surface glycoproteins) or increasing diffusive transport (e.g. via modulation of
the extracellular matrix). Furthermore, a high enough dose of virus can saturate
receptors at the center of the tumor and promote diffusion outward.
where C, and CB are the concentrations of free virus and bound virus, respectively (M); t
is the time (s); r is the radial distance (cm); D is the effective diffusion coefficient of
virus in the interstitial space (cm2s-); kc,, is the second order rate constant for binding of
free virus (MlS-1'); koyf is the first order rate constant for dissociation of bound virus from
the cell surface (s-'); 4 is the volume fraction available to virus in the tumor; CHS is the
concentration of cell surface receptors (M); a is the number of receptors sterically
blocked by the binding of each viral particle; and kd is the rate constant for degradation of
the virus (s-'), assumed to be the same for both bound and free virus.
The boundary conditions are specified by spherical symmetry at the center of the tumor
and a virus sink at the edge of the tumor:
CI 0 at r=O
ar
CI =O at r=R.
The initial conditions are
C, = Co for r < p
C, =O for r > p
with no bound virus throughout the tumor. These conditions reflect a uniform initial
concentration of virus in the center of the tumor following direct intratumor injection, a
common approach in the treatment of solid tumors (24). The injection volume is spherical
with a radius ofp.




















Equations (1) and (2) were thus recast as
s, I 2a 72  -D"a n O-a'O9)+ DaoffoB(-Da
as ?7 2 a,7 o7 - 0
aOB =DaoO (1 -a'9OB )- DaofB -Dad OBas
where a'-- a C
CHS
The differential equations (3) and (4) were solved simultaneously using a numerical finite
difference method in Matlab.
Parameter Estimation
Choice of Tumor and Initial Viral Distribution
The baseline parameter values for the model are given in Table 2.1. As we are interested
in determining the transport limitations specifically in high collagen tumors, we used as
our model tumor HSTS26T, a human soft tissue sarcoma which we have previously
shown has elevated levels of collagen (11). The tumor radius was obtained from our
previous studies (25, 26). The radius of initial viral distribution into a fibrous tumor was
measured in our previous work (10). In that study the area of initial viral distribution was
quantified by multi-photon imaging of fluorescently-labeled HSV vectors at the injection
site.
Table 2.1: Baseline model parameters
Symbol Definition
D Diffusion coefficient
kon Association rate constant
koff Dissociation rate constant
kd Degradation rate constant
Co Initial virus concentration in injection volume
R Radius of tumor
p Radius of initial viral injection
<; Volume fraction of tumor accessible to virus
CHS Heparan sulfate concentration













Estimation of Transport Parameters
The effective diffusion coefficients of particles the size of HSV have not been measured
in high collagen tumors. However, we previously measured the diffusion coefficient of
particles up to -40 nm diameter in fibrous melanoma xenografts and of-150 nm
diameter liposomes in tumors with relatively little collagen (15). By extrapolation, the
effective diffusion coefficient of HSV particles in tumors with high collagen content is
5x1 0- 10 cm2s-1. For validation we also estimated the diffusion coefficient based on the
effective medium model for hindered diffusion of a solid sphere (27, 28). In separate
studies we have previously found the Darcy permeability (K) of HSTS26T tumors to be 3
nm2 (11) and 50 nm2 (29). We should note that the Darcy permeability of collagen gels
with similar collagen content to HSTS26T tumors (30 mg/ml interstitial matrix) was
found to be 40 nm2 after correction for the effect of cells (30). Assuming the diffusion
coefficient of HSV particles in solution is equivalent to that of similarly sized liposomes,
this leads to calculated diffusion coefficients of 2xl0 -9 cm2s-1 (K = 50 nm2) and 2x10 -l0
cm2 s (K = 3 nm2). Thus, our extrapolated value from the in vivo data seems reasonable.
Estimation of Kinetic Parameters
We estimated the rate constant for degradation of HSV particles in the tumor interstitium
by measuring the rate of degradation in HSTS26T conditioned media and fitting to a first
order kinetic model (Fig. 2.2). Briefly, replication competent HSV (MGH2) particles
were incubated with 24 hour conditioned media from HSTS26T cells at several
concentrations at 370 C and pH 7.4. At various time points the media was frozen in a dry
ice/ethanol bath. The concentration of viable viral particles at each time point was
determined by titrating each sample with HSTS26T cells. The rate constant for
degradation was estimated by fitting the data to a first order rate equation. Incubation was
performed in duplicate and titration of both samples in triplicate, and the average values
were used in the analysis. It appears that proteins secreted by tumor cells can degrade
HSV since the half-time for degradation is -4.25 hrs when incubated with conditioned
media, as compared to -24 hrs when incubated with PBS.
The cell surface heparan sulfate concentration was determined experimentally for
HSTS26T cells using a DMMB dye assay according to the manufacturer's protocol
(Biocolor, Newtownabbey, Ireland). To determine the number ofheparan sulfate
molecules blocked by the binding of a single viral particle to the cell surface, we first
needed to determine the number of viral particles that can bind to a single cell. We
modeled viral particles and cells as spheres of 150 nm and 10 /#m diameter, respectively,
and assumed simple cubic packing of virus on the cell surface. This analysis showed that
that virus, rather than receptor, is limiting for HSV binding to cells (2.25x1 04 viruses/cell
vs. 1.0x107 heparan sulfate molecules/cell). While simple cubic packing most likely
cannot be achieved due to steric effects and the presence of other proteins on the cell
surface, virus internalization occurs very rapidly (tl/2 minutes) (31) and frees space on
the cell surface for other HSV particles to bind. As a conservative estimate, the calculated
value for the number of viral particles that can bind a single cell was reduced by a factor
of 2. The number of heparan sulfate molecules blocked by a single binding event was
then estimated based on the total amount of heparan sulfate per cell.
The rate constant for dissociation of bound virus from cell surface heparan sulfate was
estimated from a kinetic analysis of the binding of soluble gC to immobilized heparan
sulfate using surface plasmon resonance (20). The kinetic data fit well with a 1:1 model
(one molecule of gC binding to one molecule of heparan sulfate). The dissociation rate
constant for this process was measured at 250C. In order to adjust to the physiological
temperature of 370C, we estimated the effect of temperature on the binding rate constant
using published kinetic analyses of a variety of other proteins (32-35). From these data
we assumed an increase of-1.0 in ln(koff/T) for the temperature change of interest. While
Rux et al. measured the kinetic rate constant for individual gC molecules, we applied
them to HSV particles. Based on the spherical nature of the HSV particle, we assumed
that its attachment to the cell surface occurs at the pole, due to the interaction of a single
gC molecule with heparan sulfate.
While Rux et al. also measured the association rate constant for binding of soluble gC to
heparan sulfate (20), it was difficult to convert this value to a rate constant for HSV
particles. It is not clear whether the affinity of viral particles scales with the number of
gC molecules on its surface. To more accurately estimate the association rate constant we
experimentally assessed the binding of HSV particles to HSTS26T cells in solution (Fig.
2.3). Briefly, replication competent HSV particles were incubated with HSTS26T cells in
suspension with gentle agitation. At various time points, cells were pelleted by
centrifugation and the supernatant immediately collected and frozen in a dry ice/ethanol
bath. The concentration of viral particles at each time point was determined by titrating
with HSTS26T cells. The rate constant for degradation was estimated by fitting the data
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Estimation of Volume Fraction and Viral Concentration
There exists no measurement of the volume fraction of HSV particles or other similarly
sized particles in tumors. However, Krol et al. developed an ex vivo method to measure
the volume fraction in tumors and determined the value for dextrans of various sizes (36).
We estimated the volume fraction by using the value they measured for the largest
dextran (2x1 06 MW) in subcutaneous MCA-R fibrosarcomas.
The initial intratumor viral concentration is taken from our experiments performed with
direct injections of the oncolytic HSV vector MGH2 to treat a fibrous melanoma (10).
The concentration of virus in the tumor can be estimated since both the viral dose, 1x10 6
pfu (plaque forming units), and the volume of virus distribution - as determined by
imaging of the fluorescently-labeled viral particles directly after injection - are known
(see Chapter 3). It is important to note that pfu is not a direct measure of total number of
viral particles. In the assay for determining pfu, plaque formation depends on multiple
steps beyond simply binding and internalization of the viral particle. Thus, not every
viable HSV particle (as defined in this model) will lead to plaque formation. The total
Figure 2.3. Estimation of association rate constant. HSV particles were incubated with
HSTS26T cells in suspension with gentle agitation. The concentration of unbound
virus was determined at various time points. The data was fit to a second order kinetic
rate equation to estimate the rate constant for association. Viral degradation and
dissociation were ignored in this model. In the fit equations, the exponential factor is
given by the product of the association rate constant and the concentration of receptors.
number of HSV particles can range from 3 to 100 times the pfu, as determined by PCR
and PicoGreen staining analysis of wild type HSV (P. Grandi, personal communication).
Clearly, this will be dependent on the experiment, cell line and virus preparation. As an
approximation, we have estimated the total viral concentration from the pfu by using a
factor of 50.
Baseline Simulation
Using the baseline values, the Damkohler numbers for association (Daon), dissociation
(Daoff) and degradation (Dad) were calculated. These numbers provide a ratio of the time
scale for diffusion relative to each of these three processes. All three Damkohler numbers
are much greater than 1 (Da,, = 5.6 x 106, Daff = 2.6 x 104, Dad = 1.5 x 102), signifying
that the processes of binding and degradation occur much more rapidly than diffusion.
The dimensionless free and bound virus concentration profiles shown in Figs. 2.4A,B
reflect this. The concentrations have been normalized to the initial concentration of virus
in the injection site and the radial dimension is normalized to the overall tumor radius
(with 0 being the tumor center, 0.5 being the edge of the initial injection volume and 1
being the tumor edge). Overwhelmingly the virus remains bound to cell surfaces rather
than free in the interstitial space, with nearly three orders of magnitude more virus bound
than free at any time. Over time, the virus degrades (Fig. 2.5) and by 12 hours only -~13%
of the initial amount is left in the tumor. Very little diffusion into the adjacent tumor
space is observed, with only 4% of the remaining virus beyond the initial injection
volume at 24 hrs. To confirm that the distinctive profile is a consequence of rapid binding
and gradual degradation, the model simulation was also performed without degradation
(Fig. 2.4C) and without both degradation and binding (Fig. 2.4D). These concentration
profiles are consistent with this understanding of the viral dynamics.
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Figure 2.4. Spatial profiles for free and bound virus using baseline parameter values.
Virus concentrations have been normalized to the initial free viral concentration
throughout the injection site. The radial position has been normalized to the tumor radius.
(A) Bound virus spatial profile. (B) Free virus spatial profile. (C) Free virus spatial
profile from simulation without degradation term. (D) Free virus spatial profile from
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Sensitivity Analysis
Next, we performed a sensitivity analysis to determine the relative importance of each
parameter and to gauge the ability of various virus and tumor modifications to improve
intratumor distribution and therapeutic efficacy (Table 2.2). To compare different
simulations, various indices were considered 12 hours following the initial "injection".
The total number of free and bound viral particles in both the initial distribution volume
("virus inside") as well as the adjacent, initially uninfected region ("virus outside") was
calculated. The values normalized to the baseline simulation for each of the four species
are also given, serving as a better measure of the relative change induced by each
modification. We assessed the amount of viral spread from the initial injection site by
calculating the volume of adjacent space which contains bound virus ("volume spread").
We chose as our threshold bound virus concentration 1% of the initial injection
concentration (1.27x1 0-11M). This concentration corresponds to ~500 bound viral
Time (Hrs)
Figure 2.5. Total dose of bound virus in the initial injection volume over time. The
dose has been normalized to the initial concentration in the injection volume.
particles per cell, a number which likely leads to successful infection. The volume spread
was calculated at each time point and the maximum value was chosen to best reflect the
volume of the tumor that is infected with virus. A description of each of the simulations
follows.
Table 2.2. Sensitivity analysis"
Virus Inside Virus Outside Virus Inside Virus Outside Spread
(# viral particles) (# viral particles) (Normalized) (Normalized) Volume(Norm.)
Free Bound Free Bound Free Bound Free Bound
Baseline 2.8E+04 6.1E+06 7.2E+02 1.6E+05 1.00 1.00 1.00 1.00 1.00
Dao, x 10 2.9E+03 6.3E+06 3.OE+01 6.5E+04 0.10 1.02 0.04 0.42 0.42
Da,, / 10 2.6E+05 5.6E+06 1.9E+04 4.2E+05 9.15 0.92 27.09 2.71 3.01
Da,, / 100 1.6E+06 3.6E+06 3.6E+05 7.8E+05 57.62 0.58 497.68 4.98 7.44
Dad x 4 5.6E+01 1.2E+04 1.4E+00 3.1E+02 0.00 0.00 0.00 0.00 0.56
Dad / 3 1.2E+05 2.4E+07 2.9E+03 6.3E+05 4.09 3.98 4.06 4.02 1.75
D x 10 2.7E+04 5.8E+06 2.1E+03 4.5E+05 0.95 0.95 2.88 2.88 3.17
Co x 10 3.1E+05 6.1E+07 8.9E+03 1.9E+06 10.83 9.95 12.31 11.97 1.90
Co x 100 9.5E+06 4.8E+08 1.1E+06 1.4E+08 331.94 78.32 1493.53 906.18 8.63
x 3 8.3E+04 6.OE+06 3.5E+03 2.5E+05 2.92 0.98 4.84 1.61 1.75
/ 3 9.6E+03 6.2E+06 1.5E+02 9.9E+04 0.34 1.01 0.21 0.64 0.71
D x 10 and Da,, / 10 2.2E+05 4.8E+06 5.9E+04 1.3E+06 7.75 0.78 82.24 8.23 10.28
D x 10 and Da,, / 100 9.5E+05 2.1E+06 1.OE+06 2.3E+06 33.47 0.34 1449.71 14.53 26.87
* Values shown are for time = 12 hours following the beginning of the simulation, except for spread volume
# Values for changes in Dao,f are nearly equivalent to values for opposite and proportional changes in Dao
Binding Kinetics
We first examined the effect that changes in virus binding characteristics would have on
its distribution. Since virus binding dominates in the baseline simulation, we analyzed the
extent to which a decrease in affinity to heparan sulfate would improve distribution. A
ten-fold decrease in the affinity increases both the amount of bound virus in the adjacent
space and the spread volume by nearly 3-fold (Fig. 2.6A). This change in the affinity
constant was chosen to reflect possible changes to the virus, itself. Rux et al. found that
deletion of residues 33-123 of gC results in an order of magnitude increase in its KD (20).
Furthermore, it has been shown that the gB-heparan sulfate interaction is the second
strongest between HSV and cells, with a binding affinity that is an order of magnitude
lower than for gC (20, 21). Thus a 10-fold decrease in the affinity constant approximates
the change that would occur if gC is modified or deleted.
Beyond gC and gB, the interaction of other viral envelope glycoproteins with cell
surfaces is less well studied. It has been found that the binding affinity of gD with its cell
surface receptor is an order of magnitude lower than for gB-heparan sulfate, and two
orders of magnitude lower than for gC-heparan sulfate (37). Thus we examined the effect
of a two orders of magnitude decrease in the affinity, which would reflect changes to both
gC and gB. This leads to a greater than 7-fold increase in the spread volume (Fig. 2.6A).
As expected the amount of bound virus in the initial injection volume decreases as a
greater fraction of virus is free and diffuses out of this volume. However, there is still
-102 bound viral particles per cell in this region, suggesting that we are not at the point of
diminishing returns for overall cell infection.
Next we assessed the effect of a ten-fold increase in affinity. The spread volume
decreased by more than a half, with a greater than two-fold decrease in the amount of
bound virus in the adjacent region (Fig. 2.6A). When changes to the dissociation constant
(i.e. Daoff) were analyzed, we found proportional and opposite effects when compared to
changes in the association constant (i.e. Da,,). Thus, to avoid repetition these results are
not displayed in Table 2.2. We should also note that a change in Da,, can reflect a change
in either k,, or CHS. Thus, binding affinity can be reduced by changing the virus, as
mentioned above, or by finding tumors that contain less heparan sulfate receptors for cell
surface binding.
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Figure 2.6. Effect of parameter modifications on bound virus concentration and spread
volume. The values for the total concentration of bound virus outside the initial
distribution volume and the spread volume are shown, normalized to the values in the
baseline simulation. Values are for 12 hours after the beginning of the simulation for the
amount of bound virus outside and are maximum values for volume spread. (A) Effect of
changes in the binding kinetics on virus distribution. (B) Effect of changes in the
degradation rate constant and diffusion coefficient on viral distribution.
Degradation
Our experiments showed that the t/ 2 for degradation of HSV particles at 370C in tumor
cell conditioned media is -4 hrs, while t/12 - 24 hrs in PBS. However, these in vitro
experiments may not completely capture the conditions in vivo, where the concentration
of extracellular factors may be different. It is therefore important to analyze the
I
I I
sensitivity of the model to this parameter. As this model does not take into account viral
internalization - a process that occurs on the order of minutes - few insights can be
drawn from changes in total bound virus induced by altering Dad. Rather it is more useful
to assess changes in the spread volume, which is affected by degradation since diffusion
of free virus is a slow process. When the virus half life is decreased to 1 hr, nearly all free
virus is degraded by 12 hrs. The maximum spread volume is only several microns from
the injection volume, and the spread volume is half of the baseline value (Fig. 2.6B).
Conversely, increasing the virus half-life by a factor of 3 led to a 4-fold increase in the
amount of virus in each compartment. Interestingly, the distribution was increased less
than 2-fold (Fig. 2.6B), suggesting that while degradation occurs quickly, the limited
spread of the virus is mainly a consequence of rapid binding.
Diffusion
Altering the diffusion coefficient can have an effect on the distribution of virus in the
tumor. Our previous work has shown that the effective diffusion coefficient in a tumor
correlates negatively with collagen content (11). In this model, we have chosen our
effective diffusion coefficient to reflect transport in a collagen-rich fibrosarcoma. Thus
we have chosen a particularly low value. Based on a comparison of the diffusion
coefficient of various tracer molecules in tumors with high and low levels of collagen
(15), we believe that a 10-fold increase in D more accurately reflects the conditions in
less fibrous solid tumors. Furthermore, based on previous work we estimate that this
increase in diffusion coefficient is possible for large particles such as HSV in high
collagen tumors with the addition of collagen-modulating factors (11, 38). An order of
magnitude increase in the diffusion coefficient results in a 3-fold increase in both the
amount of virus outside the initial injection volume and the spread volume (Fig. 2.6B).
Thus, the model predicts that an oncolytic HSV vector would be more effective in
treating a low collagen tumor than a high collagen one. It also suggests that matrix
modification may be a useful method to improve viral vector distribution in those tumors
with a significant amount of collagen and hindered diffusion.
Volume Fraction
The volume fraction of tumor accessible to virus has the potential to affect therapeutic
response since it influences virus accumulation and distribution in the tumor. The
variation in volume fraction for particles the size of HSV has not been determined in
different tumors. However, the interstitial volume of tumors - which plays an important
role in determining the available volume fraction - has been measured in various tumors
and found to range from 10-60% (39-41). In a fibrosarcoma with an interstitial fluid
space of -50%, the accessible volume fraction for large macromolecules (molecular
weight > 105) was found to be less than 0.1. Based on these data, to approximate various
tumors we decided to run the simulation with a 3-fold increase (0 = 0.15) and 3-fold
decrease (4 = 0.017) in the volume fraction. A 3-fold increase in the volume fraction
results in a -60% increase in the amount of bound virus outside the initial injection
volume and the distance spread. In contrast, a 3-fold decrease reduces the spread volume
by nearly a third (Table 2.2). These results show that variations in volume fraction
between tumors may have an effect, but it may not be overwhelming. Relative to other
parameters, viral distribution appears insensitive to this parameter.
Initial Dose
We analyzed the effect of input viral dose. A 10-fold increase in initial viral
concentration resulted in nearly equivalent increases in viral concentrations in each of the
compartments, and only a two-fold increase in the spread volume (Table 2.2). A slightly
greater than proportional increase in the amount of virus outside the initial distribution
volume was observed, suggesting that we are approaching the viral concentration
necessary to saturate receptors. Indeed, for a 100-fold increase in the viral concentration,
nearly 90% of the virus inside the injection site is unbound (Fig. 2.6A). The virus
behaves like a moving front of bound virus, with degradation occurring over time. The
amount of virus outside the initial injection volume has increased by three orders of
magnitude compared to the baseline simulation and the volume spread has increased by
more than 8-fold.
These results suggest that one simple way to improve viral distribution and perhaps
efficacy is to increase the dose to saturate receptors and promote diffusion from the
injection site. However, the model does not take into account loss of virus into the
systemic circulation during infusion. Based on studies with adenoviral vectors, this may
reduce the actual dose within the tumor by as much as an order of magnitude (42).
Furthermore, in this work we have modeled relatively small tumors found in certain pre-
clinical experimental models (1 mm diameter). Scaling up to human tumors would
require an increase in dose of at least an order of magnitude. Taking these into
consideration, at least a four orders of magnitude increase in dose would be necessary to
achieve the improvements in distribution shown in Fig. 2.7A. This dose would be orders
of magnitude beyond what has been used in human clinical trials (6). Such a high dose
would likely compromise the safety of an oncolytic HSV vector and would most certainly
be impractical to obtain, given the relative difficulty of purifying HSV at high titers.
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Figure 2.7. Spatial profiles for bound virus using adjusted parameter values. (A) Model
simulation with the initial dose increased 100-fold, while all other parameters are kept at
their baseline value. (B) Model simulation with the diffusion coefficient increased by a
factor of 10, and Da,, decreased by a factor of 100, with all other parameters kept at their
baseline value.
Implications and Limitations
Several limitations remain in the present model: (a) it does not take into account binding
of the virus to extracellular matrix components (including heparan sulfate not on the cell
surface) or other cell surface molecules and receptors; (b) it lacks a complete description
of virus clearance, particularly via the systemic circulation, which has been found to be
quite significant for intratumorally injected virus; (c) it ignored downstream events such
as bound virus internalization and replication; (d) it assumes a uniform distribution of
virus in the center of the tumor following intratumor injection, ignoring the effects that
matrix structures and infusion conditions can have on convective delivery during this
process.
Nevertheless, the model has exposed some important characteristics of intratumor vius
transport. The simulations show that rapid binding and impaired diffusion limit the
distribution of virus in the tumor. After injection into the interstitial space, virus will
quickly bind to cells. Even in the absence of binding, diffusion is a relatively slow
process due to the large size of the virus. It has been observed experimentally that the
spread of virus from the injection site can be quite limited (10). This model offers one
possible explanation for this phenomenon for HSV. This finding has significant
implications for the treatment of tumors with replication-competent HSV vectors, such as
oncolytic vectors. Progeny virus that are released into the extracellular space following
cell lysis will be subject to the same limited interstitial transport and will be able to infect
cells only in close proximity. Using multiphoton imaging we have observed the
propagation ofoncolytic HSV in individual tumor xenografts and found that progeny
virus typically infects only neighboring cells (10). The model results are consistent with
this observation, although direct spread from cell to cell through junctions likely
contributes, as well (43).
Since the initial virus distribution in the tumor is critical for an oncolytic virus to control
tumor growth, this also points to the importance of the method of viral delivery. For a
direct intratumor injection, the rate and volume of infusion, tumor permeability and
hydraulic conductivity and the number of injection sites will all be key parameters. Any
choice of parameter values which improves the initial distribution may enhance treatment
outcome. Indeed, a study has already shown that fractionated injection of an oncolytic
HSV in multiple sites is advantageous to a single injection (44). Bobo et al. showed that
the distribution of large molecules in the brain could be improved by prolonged infusion
(45). They also showed that the volume of distribution increased linearly with the
infusion volume. However, enhancing the distribution of therapeutics by optimizing
infusion parameters may not be a viable option for many tumors. Boucher et al. found
that even at low flow rates, albumin infused in the center ofa fibrosarcoma distributed
asymmetrically from the source (46). Fluid accumulated in necrotic regions and at the
surface of the tumor, with channels of fluid connecting these regions. The extreme
stiffness of these tumors - likely due to the composition and structure of the extracellular
matrix - appeared to contribute to the difficulty in obtaining uniform and widespread
delivery. Given this observation, an alternative method to enhance intratumoral infusion
may be to increase the permeability and hydraulic conductivity of the tumor. In Chapter 5
we use the matrix degrading proteases matrix metalloproteinase-1 and -8 to modify the
tumor extracellular matrix, increase hydraulic conductivity and enhance the distribution
and efficacy of intratumorally injected oncolytic HSV vectors.
The model suggests that certain tumors may be more responsive to oncolytic HSV
therapy than others, based on such factors as the concentration of heparan sulfate and the
composition of the extracellular matrix (which determines the effective diffusion
coefficient and accessible volume fraction). It also points to various methods of virus and
tumor modification which can enhance the efficacy of oncolytic HSV. Two such
modifications are (a) a decrease in the binding affinity via alteration of the viral envelope
and (b) an increase in the effective diffusion coefficient of virus through degradation of
tumor collagen. A model simulation with both of these modifications shows significantly
improved virus distribution (Fig. 2.7B). While modified HSV vectors with mutations in
gC and gB have been developed (22, 23, 47), these changes have yet to be incorporated
into oncolytic vectors. Whether these changes can improve viral spread and enhance
efficacy is an exciting question that we hope will be answered shortly. A second
approach to overcome rapid binding and enhance diffusion is to pre-block virus binding
sites in the tissue, similar to the approach previously developed for antibodies (48). In
theory, virus particles would diffuse farther but then compete for binding sites and
eventually infect cells distant from the injection site. This method has the advantage of
not altering the intrinsic affinity of the virus, which may have unforeseen consequences
and decrease infection efficiency. As for modulation of tumor fibrillar collagen, we
validate our predictions experimentally using bacterial collagenase in Chapter 3 (10). The
challenge with this technique is finding clinically relevant ways to degrade the matrix
while limiting the negative effects these changes may have on tumor cell invasion and
metastasis.
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Chapter 3: Enhancement of Viral Vector Delivery with Bacterial
Collagenase
Portions of the chapter have been taken from:
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melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector." Cancer
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Introduction
Oncolytic vectors, mutant viruses that replicate preferentially in tumor cells, have shown
promise in various preclinical tumor models (1, 2). Oncolytic viral therapy employs a
novel method of tumor destruction mediated by viral replication and selective lysis of
cancer cells (3, 4). The creation of more virus by infected tumor cells and resultant
infectious spread improves over passive forms of therapeutic delivery (5, 6). Early phase
human trials of G207, an oncolytic herpes simplex virus (HSV) vector, for treatment of
recurrent malignant glioblastomas have demonstrated both safety and efficacy (7).
However, the inability to efficiently propagate and infect cells distant from the injection
site limits the capacity of oncolytic viruses to achieve consistent therapeutic responses
(8). In this study, we show that fibrillar collagen, the major barrier to macromolecular
transport in the tumor interstitium (9-11), also limits viral distribution within tumors.
Direct degradation of the fibrillar collagen network improves viral distribution, leading to
improved oncolytic viral therapy.
Materials and Methods
Viral vectors
The HSV-1 recombinant viruses used in this study were the replication defective mutant
Gal4 (ICP4-, lacZt; from Neal DeLuca, University of Pittsburgh (12)) and MGH2 (ICP6,
y34.5-, eGFP+; from E. Antonio Chiocca and Yoshi Saeki, The Ohio State University
(13)). MGH2 is a replication conditional virus attenuated by the deletion of two
nonessential viral gene, ICP6 and y34.5 (14). Virus replication is impaired in non-
dividing cells but not tumor cells.
Gal4 and MGH2 stocks were propagated in E5 and E26 cells (from Neal DeLuca (15)),
respectively, which supply the HSV-1 ICP4 protein (E5) or HSV ICP4 and ICP27
proteins (E26) in trans. To obtain GFP-labelled HSV particles, E5 and E26 cells were
transfected with a plasmid encoding the fusion protein VP16-GFP (pVPl6-GFP (16)) and
infected with Gal4 and MGH2, respectively. After purification and concentration the titer
of each virus preparation was quantified by counting lacZ-positive cells for Gal4 and
GFP-positive cells for MGH2.
Dorsal skinfold window preparation
Human melanoma Mu89 cells were grown in dorsal skinfold chambers in SCID mice as
described previously (9). All animal experiments were done with the approval of the
Institutional Animal Care and Use Committee.
Injection and imaging of labeled vectors and tracers
For dorsal chamber tumor studies, HSV vectors labeled with VP 16-GFP were mixed with
either 0.2 tg/gtl bacterial collagenase (Sigma, C0773, St Louis, MO) or PBS, to a final
titer of lxl06 t.u./#l. For microsphere experiments, quantum dot (QD)-encoded silica
microspheres were synthesized according to a previously developed procedure (17). For
all injections, 1 il of solution was infused into the tumor at constant pressure (-1 01/10
min) using a glass micropipette connected to a syringe pump. Images were obtained using
a custom-built multiphoton laser scanning microscope (18) using a 20X/0.5NA objective
lens. Excitation was at 880 nm, with simultaneous detection of SHG (9) via a 435DF30
emission filter, and GFP via a high-pass 475 dichroic and a 525DF100 emission filter.
Cascade Blue dextran was visualized by exciting at 780 nm and imaging the same region
(for Cascade Blue dextran and GFP), followed by image registration. Microspheres
(containing 642 nm maximum emission QDs) were imaged with a 610DF70 emission
filter. Three dimensional image stacks containing 20 images of 5 gm thickness were
obtained wherever fluorescence intensity from the injected particles was detected. A
maximum intensity z-projection of each colored stack generated a 2D image. Images of
consecutive adjacent regions in the x and y directions were combined into a montage,
generating a single image of the entire injection site.
Image analysis
The pixel intensities of collagen (red pixels) and injected particles (viral vectors, green
pixels; dextran, blue pixels) were spatially compared along lines drawn perpendicular to
the periphery of virus containing regions. Analysis was performed in 5 distinct image
stacks and at different depths, for a total of 20 lines measured within each tumor. The
mean pixel intensities were plotted as a function of the relative distance from the
observed interface with fibrillar collagen. All lines were registered such that the largest
change in SHG intensity was maintained at the origin of the graph.
For quantification of viral vector distribution following injection, the entire area of viral
distribution was outlined on the images. The border of the viral focus was determined as
the location at which the intensity dropped to 10% of the mean intensity at the center of
injection. The calculation of the area was performed with imaging software (ImageJ, U.
S. National Institutes of Health, Bethesda, MD, http://rsb.info.nih.gov/ij/).
Flank tumor growth delay
Mu89 cells were implanted subcutaneously in the flank of SCID mice and allowed to
reach 100 mm3 average volume. Mice were then randomized into 4 groups (6-7 animals
per group) and given 10 ld intratumoral injections of either PBS; 1.0 pg collagenase;
1x106 t.u. MGH2; or a mixture l x106 t.u. MGH2 and 1.0 gg collagenase. A second
injection was performed two days later. Tumor volume was measured every 2-3 days and
calculated as volume = 7rAB 2/6, where A and B are maximum and minimum diameters,
respectively. Mice died from natural progression of disease or were euthanized when (a)
tumor mass exceeded a size of 2,000 mm 3 or (b) premorbid behavior was noted. For
tumors failing to reach ten times initial volume due to morbidity, the time to last
measurement substituted as a conservative approximation of growth.
Metastasis assay
Tumors were grown subcutaneously in the leg of SCID mice. At a size of -100 mm3 they
were treated with an intratumor injection with either 10 il of PBS or 10 gil of PBS with
1.0 gg collagenase, followed by a similar injection two days later. Tumors were allowed
to grow to 500 mm 3, at which point the tumor-bearing leg was amputated. Any bleeding
was controlled and the wound closed with wound clips. Six weeks following primary
tumor resection, the mice was euthanized by an intraperitoneal injection of sodium
pentobarbital (200 mg/kg). A full gross autopsy was performed to locate visible
metastatic nodules and the lungs were examined histologically for micrometastases.
Immunohistochemistry protocolfor herpes simplex virus
1. Dry slides overnight at RT
2. Incubate in ice cold acetone at -200 C for 10 minutes
3. Wash with PBS 3x for 3 minutes
4. Block for 1 hr at RT with 10% normal goat serums, 1% BSA, 0.1% triton solution
5. Incubate with primary antibody (polyclonal rabbit anti-HSV type I, Dako, Glostrup,
Denmark) at a dilution of 1:100 overnight at 40C
6. Wash with PBS 3x for 3 minutes
7. Incubate with secondary antibody (Cy3 anti-rabbit) at a dilution of 1:200, 30 min RT
8. Wash with PBS 3x for 3 minutes
9. Mount sections with Vectashield mounting media with DAPI (Vector Laboratories,
Burlingame, CA)
Statistical analysis
Data are expressed as mean ± SEM. Statistical significance between groups was
determined by an unpaired Student t-test. Statistical analysis was performed using
StatView 4.51 software (SAS Institute, Inc., Cary, NC). Differences were considered
statistically significant for P < 0.05.
Results
Distribution of virion particles is hindered by collagen rich regions
To quantify virus distribution, one microliter containing lx106 viral transducing units
(t.u.) of VP16-GFP labeled non-replicative HSV-1 virions (Gal4) was directly injected
into Mu89 human melanomas grown in dorsal skin windows in SCID mice. In vivo
multiphoton imaging of viral particles was performed approximately 30 minutes
following injection with simultaneous second harmonic generation (SHG) imaging of
fibrillar collagen. Viral particles distributed primarily within collagen-free areas of the
tumor, with limited penetration into collagen-rich regions (Fig. 3.1A). To quantify viral
penetration, pixel counts of collagen (SHG) and virus (GFP) were measured along lines
perpendicular to the periphery of virus containing regions (one example line is shown in
Fig. 3.1A). Averaging over 20 lines per injection revealed an inverse correlation between
collagen and viral particles, such that an increase in the amount of fibrillar collagen
present corresponded to a sharp decrease in virus signal (Fig. 3.1B). While collagen is
known to hinder macromolecular transport (10, 11), nearly complete exclusion to this
extent has not been previously observed. To directly compare viral distribution with
another macromolecular tracer, Cascade Blue-conjugated 2x106 molecular weight
dextran tracer molecules (RH - 20 nm) were co-injected with HSV vectors. Whereas the
dextran penetrated into collagen rich regions, viral particles were excluded (Fig. 3.1A,B).
In the collagen containing regions, the mean dextran intensity is significantly greater than
the mean virus intensity when both are normalized to the maximum signal from each
channel (P < 0.001). To further clarify the role of particle size in collagen exclusion,
quantum dot-loaded microspheres similar in size to HSV particles (- 150 nm diameter)
were directly injected into Mu89 tumors. As with HSV particles, these microspheres were
excluded from collagen rich tumor areas (Fig. 3.1E). The microsphere distribution area
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Figure 3.1. Viral vector distribution following intratumoral injection. (A) Multiphoton
images of Mu89 melanomas 30 minutes after intratumoral injection of VPl6-GFP
labeled Gal4 vectors (green), either alone (upper image) or with Cascade blue-
conjugated dextran (blue, lower image). Second harmonic generation (SHG) signal
denotes fibrillar collagen (red pseudocolor). HSV vectors localized in extracellular
spaces around individual tumor cells and were excluded by areas of intense SHG
signal. In contrast, the smaller dextran tracer penetrated regions rich in fibrillar
collagen. (B) Relative localization of collagen and injected particles determined by
pixel analysis. Spatial comparison of pixel intensities was performed for collagen (red
pixels) and either viral particles (green pixels; upper plot) or dextran (blue pixels;
lower plot). Analysis was performed along lines drawn perpendicular to the border of
SHG signal, and mean values plotted. A representative image and line are shown for
each case (A, yellow lines). Collagen and viral localization in the tumor are anti-
correlative. (C) Multiphoton images of viral vector distribution following co-injection
with collagenase (left) compared with injection of virus alone (right). Each image is a
montage of several multiphoton images. The area of distribution is outlined in blue in
Disruption of the collagen network improves virus distribution and gene expression
To test whether disruption of collagen could improve viral penetration into tumors, viral
vectors were co-injected with bacterial collagenase (0.2 tg/gtl). Collagenase increased the
area of viral distribution by nearly 3-fold compared to control injections (Fig. 3.1D).
Rather than distributing into restricted regions bounded by fibrillar collagen, vectors
spread more uniformly from the injection site upon collagenase treatment (Fig. 3.1C).
Collagenase enhances the efficacy of oncolytic viral therapy
The oncolytic virus MGH2 has the same backbone as G207 (14), but carries the GFP
reporter gene instead of lacZ. MGH2 replicates in Mu89 melanoma cells in culture,
resulting in GFP expression and cell lysis within 24-48 hours. lxl06 t.u. of MGH2 were
injected into Mu89 tumors as before. Low resolution fluorescence microscopy one day
following injection showed that the area of infection was localized to only a small
proportion (-15%) of the entire tumor mass, corresponding to the site of injection (Fig.
each case. (D) Comparison of the area of viral vector and microsphere distribution
following intratumoral injection. Areas measured from a maximum intensity projection
of 10 images taken -30 minutes following injection. Collagenase and virus co-injection
resulted in a nearly 3-fold increase in the area of viral distribution compared with
microspheres and HSV particles alone (P < 0.05). (E) Multiphoton images of
microsphere distribution following intratumor injection. Microspheres shown in green
and SHG in red pseudocolor.
3.2A middle). Even 11 days following the initial injection of MGH2, viral vectors could
not penetrate sufficiently to infect the entire tumor mass (Fig. 3.2A bottom). No
significant treatment response was observed in any of the tumors injected with MGH2
alone or with bacterial collagenase alone (Fig. 3.2A,C bottom).
To confirm that collagen was the cause of this limited tumor cell infection, high
resolution multiphoton imaging of viral vectors, transduced cells and fibrillar collagen
was also performed (Fig. 3.3). Imaging of the GFP-labeled MGH2 particles immediately
after injection showed that, as before, virus spread is limited by fibrillar collagen (Fig. 3.3
left). Imaging of infected tumors cells (which express large amounts of GFP) three days
later shows that the area of infection corresponds to the initial area of virus distribution
and is surrounded by fibrillar collagen (Fig. 3.3 middle). It appears that virus was not able
to diffuse and infect cells beyond the initial injection volume. At 8 days post-injection,
GFP expression is severely diminished as the initially infected cells have died and









Figure 3.2. Effect of collagenase on oncolytic viral therapy. Low resolution microscopic
images of dorsal chamber Mu89 melanomas treated with the oncolytic vector MGH2 in
combination with PBS (A) or MGH2 in combination with collagenase (B). Collagenase
treatment alone is shown for comparison (C). N=4 for all three treatment groups.
Representative brightfield images of tumors prior to injection (tumors outlined in black,
top panels). Representative fluorescent microscopic images of tumors 1 day (middle
panels) and 11 days (bottom panels) after injection. Infection of tumor cells was
detected by expression of the reporter gene GFP (encoded by the virus). Co-injection of
MGH2 and collagenase resulted in a greater distribution of infected cells (B, middle
panel), relative to injection of MGH2 alone (A, middle panel). At 11 days, regression of
Day 0 - Injection Day 3 Day 8
Figure 3.3. Viral distribution and tumor cell transduction following intratumor injection
of oncolytic virus MGH2. Representative high resolution multiphoton images of
injected MGH2 and infected tumor cells (both green) and second harmonic generation
(red pseudocolor). Left: images taken of GFP-labeled MGH2 30 minutes following
intratumor injection. Middle and Right: images taken of MGH2-infected cells
(expressing GFP) 3 and 8 days following injection in the same tumor. Fibrillar collagen
surrounds the injected virus and infected cells. Scale bar is 250 Itm.
the tumor (as evidenced by absence of tumor vasculature) was achieved with MGH2 and
collagenase co-injection (B, bottom panel), while no significant change in volume was
observed with MGH2 treatment alone (A, bottom panel). Collagenase treated tumors
recover from any induced hemorrhage by day 11 (C, lower panel).
In contrast, when the same amount of oncolytic virus was co-injected with collagenase
(0.2 gg/tl), the initial viral distribution was greater relative to virus alone, translating into
an improved area of tumor cell infection (Fig. 3.2B middle). Therapeutic response was
observed in all four collagenase co-treated tumors, with a significant decrease in tumor
size in two cases (Fig. 2B bottom).
We then tested if the co-injection of collagenase and MGH2 would increase the
therapeutic efficacy of MGH2 over longer time intervals. When Mu89 tumors growing in
the flank of SCID mice reached 100 mm 3, they were injected intratumorally with either 1
gg collagenase, 1x10 6 t.u. of MGH2, or both collagenase and MGH2, followed by
similar injections two days later. Control tumors were injected with PBS alone. The time
for the tumor to reach ten times the initial volume (mean + SEM) was compared for each
group (Fig. 4). Both collagenase treatment alone (19 + 1 days) and MGH2 injection alone
(27 + 3 days) had no significant effect on tumor growth compared to PBS control (24 + 3
days) (P > 0.05, both cases). With MGH2 treatment alone, one tumor showed marked
regression, but recurred after 10 days. Co-injection of MGH2 with collagenase (50 + 9
days) significantly delayed the growth of tumors compared to all other treatment groups
(P < 0.05 for all cases). Two out of seven tumors failed to grow to 200 mm3 even 60 days
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Days
Treatment Time to 10- Number of
fold Increase mice with
In tumor size significant
tumor
regression
PBS 23 1 3 days 0/6
Collagenase 19 1 days 0/6
MGH2 27 ± 3 days 1/6
MGH2 and 50 ± 8 days 3/7Collagenase
Figure 3.4. Effect of collagenase on MGH2-induced tumor growth delay. Tumors were
grown subcutaneously in the hind flank of SCID mice. When tumors reached -100 mm3 ,
animals were divided into four groups (n = 6-7) and treated twice (day 0 and day 2) with
10 tll of PBS (green), collagenase (0.1 pg/pl) (black), MGH2 (lxI06 t.u.) in PBS (blue),
or MGH2 (lxI06 t.u.) and collagenase (0.1 pg/pl) in PBS (red). (A) Tumor volumes were
measured every 2-3 days and the time to reach a given volume was expressed as mean ±
SEM for each group. (B) The time to reach ten times the initial volume was compared.
There was no significant difference between PBS (23 ± 3 days) and either collagenase
treatment alone (19 + 1 days) or MGH2 alone (27 + 3 days) (P > 0.05 for both cases).
However, MGH2 and collagenase co-treatment induced a significant tumor growth delay
(50 + 8 days) relative to all other groups (P < 0.05 for all cases).
Improved efficacy is due to initial improved distribution of viral particles
To investigate the mechanism of improved efficacy, tumors were treated as before with
MGH2, either alone or with collagenase, and analyzed two days after the second
injection. Tissue sections were stained for structural virion proteins, counterstained for
nuclei (DAPI), and imaged for GFP expression using confocal microscopy to determine
viral distribution. As expected, HSV antigen was present within and surrounding cells
expressing GFP. In MGH2-treated tumors, virion particles and infected cells distributed
in a localized fashion reminiscient of the needle track (Fig. 5A). In contrast, for MGH2
and collagenase treatment, a diffuse distribution of infected cells was observed
throughout the entire tumor section, spanning an area of up to 3 x 7 mm (Fig. 5B). Later
timepoints showed continued viral spread, but only within collagen free areas.
50 pm
Figure 3.5. Immunohistochemical analysis of the effect of bacterial collagenase on viral
infection. Representative tissue sections of subcutaneous Mu89 tumors two days
following injection with either (A) MGH2 alone or (B) MGH2 and collagenase were
labeled with anti-HSV antibodies. GFP expression from MGH2-infected cells (green),
HSV proteins detected with Cy3-conjugated secondary antibodies (red) and nuclear stain
DAPI (blue) are shown.
I
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Bacterial collagenase does not affect metastatic behavior
Matrix modification has long been linked to tumor cell invasion and metastasis. Thus, in
order to assess if improving the efficacy of oncolytic viruses by collagen degradation is a
viable technique for the treatment of patients, we performed a metastasis assay. Mu89
tumors were grown subcutaneously in the leg of SCID mice and treated with collagenase
as before. Following tumor growth to 5 times the initial size, the primary tumor was
resected. An autopsy was performed 6 weeks later to identify metastatic nodules. There
was no increase in metastasis observed with collagenase treatment (Table 3.1). Due to the
low incidence of metastasis in this study, the assay was repeated for two other tumors:
human soft tissue sarcoma HSTS26T and spontaneous murine osteosarcoma P0107. In
both cases no lymph node and lung metastasis was observed in either treatment group.
Thus, it appears that bacterial collagenase treatment at this concentration does not
enhance metastatic behavior.
Table 3.1. Effect of bacterial collagenase on lymph node and lung metastasis
Treatment No. of mice0  No. of animals with No. of animals with Jung
lymph node metastasisb metastasis
PBS 4 1/4 0/4
Bacterial Collagenase 4 1/4 0/4
a in both treatment groups, primary tumor regrowth was occurred in one animal
b in both treatment groups, lymph node metastasis was observed in the animal in which primary tumor
regrowth occurred
Discussion
The development of strategies to improve both the initial vector distribution within
tumors and the ability of these vectors to propagate through the entire tumor mass is
critical to the success of oncolytic viral therapy (2). Previous reports show that protease
pretreatment can increase the therapeutic efficacy of a non-replicative viral vector (19).
However, the mechanism of improved efficacy was undefined due to the use of
nonspecific digestive enzymes - normally used to dissociate tissues - which degrade
multiple extracellular matrix components. Thus, we wished to determine whether fibrillar
collagen - previously shown to be a major barrier to macromolecular diffusion in tumors
(10, 11) - is the matrix component which limits viral distribution in certain tumors.
Our results demonstrate the important role that fibrillar collagen can play in regulating
the initial distribution of viral vectors in certain fibrous tumors. Whereas the smaller
tracer particles distributed relatively uniformly within the tumor, the vast majority of
larger HSV virions were located only in collagen-poor areas. Furthermore, silica
microspheres similar in size to viral particles - but lacking their ability to bind to cell and
matrix proteins - were excluded from collagen. This suggests that the effective pore size
cutoff of the collagen network is smaller than the size of these viral particles. This may
have a significant impact since many tumors in humans show extensive stromal
infiltration with extracellular matrix and collagen deposition (20).
Fibrillar collagen is also important in the propagation ofoncolytic viral vectors through
the tumor. Oncolytic vectors are thought to overcome some of the delivery issues faced
by non-replicating viral vectors through their ability to propagate on site in tumors
(thereby amplifying the input dose) and spread from tumor cell to tumor cell. We found
that the collagen network, in addition to restricting the initial distribution, limited the
maximal spread of MGH2 infection within the tumor. Tumor cell infection remained
confined to a small area and the tumor continued to grow. Co-injection of MGH2 with
collagenase resulted in a broad, uniform distribution of viral particles and infected cells,
with substantial tumor regression and enhanced efficacy. This dispersed distribution of
virus can improve therapeutic outcome in several ways: 1) the broad initial virion
distribution improves the chance that viral vectors can penetrate all regions of the tumor;
2) the occurrence of multiple infections of the same tumor cell decreases, while the
number of distinct tumor cell infections increases; and 3) once the virus replicates and
lyses the cell it has infected, it has access to a greater number of previously uninfected
neighboring cells. All together, these processes can lead to increased oncolytic activity,
as shown schematically in Fig. 3.6.









Researchers have developed other methods to try to overcome the limited distribution of
oncolytic vectors in tumors (21). Some use multiple injections, either on successive days
or with fractionation of the dose at multiple sites (22). However, in the absence of
extracellular matrix modification, viral distribution at each individual injection site would
still be limited by collagen. Indeed, a phase II trial with an oncolytic adenoviral vector
showed limited improvement in efficacy even with daily injections that included
fractionation (23). Alternatively, combination therapy with either radiation or
chemotherapy is often employed to improve oncolytic activity (24). Collagenase
treatment is compatible with combination therapy and could further improve efficacy.
This may be a complementary therapy for combination with radiation, which can induce
fibrosis and lead to an increase in interstitial collagen content (25).
Figure 3.6. Schematic model of improvement in oncolytic viral distribution and tumor
cell infection with collagenase treatment. Following direct intratumor injection, viral
spread (pink area) is limited by fibrillar collagen (red lines) and results in a cluster of
infected cells (light green). The collagen network also restricts the distribution of
subsequent viral progeny and tumor cell infection beyond the initial injection site is not
achieved. In contrast, co-injection of virus with collagenase results in a more diffuse
distribution of viral particles and a greater number of initially infected cells (light
green). Viral particles released by these cells have greater access to neighboring
uninfected cells. This process results in more widespread secondary infection (dark
green) and ultimately greater therapeutic efficacy.
We noted that intratumoral haemorrhage occurred in many tumors treated with
collagenase. While bleeding from collagenase treatment alone did not affect tumor
growth, this phenomenon demonstrates the complex interactions between the
extracellular matrix and cells within the tumor, including both tumor and host endothelial
cells. We observed no increase in metastasis when tumors were treated with bacterial
collagenase (Table 3.1) and a previous study has shown that direct injections of
collagenase/dispase and trypsin did not affect metastasis (19). Despite these encouraging
results, it is still possible that collagenases may have a negative effect on tumor cell
invasion and metastasis, perhaps at different doses. The development of this matrix-
modulating technique for clinical applications may require the use of specific matrix
proteases, such as MMP-8, which degrades collagen and has been shown to decrease
metastasis (26).
In conclusion, we determined that even with the on-site generation of viral particles
provided by the replication-competent nature of an oncolytic HSV vector, fibrillar
collagen still prevents viral spread throughout the tumor in a melanoma model. Collagen
network disruption increases initial vector distribution and subsequent propagation
through the tumor mass, significantly improving therapeutic outcome. This result has
implications for other viral particles, gene delivery strategies and nano-technology based
delivery systems, as all face the problem of insufficient delivery to the target cells.
Furthermore, any method decreasing tumor collagen content may have similar effects.
These findings suggest ways to increase the potency of gene therapy in certain types of
cancer and other diseases.
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Chapter 4: Degradation of Tumor Collagen with Recombinant
Human Enzymes
Introduction
While the application of bacterial collagenase to degrade tumor collagen and improve the
transport of therapeutics has been advanced as a proof of principle concept (1), moving
this technique into the clinic will require the use of a human enzyme or an agent which
can upregulate the expression of a such an enzyme in tumors. Our lab has previously
worked with the peptide hormone relaxin, which is primarily produced during pregnancy
to stimulate collagen remodeling in the reproductive tract, but has recently been found to
have pleiotropic effects (2-4). We found that chronic relaxin treatment accelerated
collagen turnover and increased diffusive transport (5). The mechanism by which relaxin
modifies collagen is still unclear. It has been found in different systems to affect both
collagen production (6-8) and degradation (9, 10). Relaxin most likely initiates a
signaling cascade which reduces collagen deposition by fibroblast and upregulates
collagenase expression or induces their activation. However, recent reports suggest that
relaxin may enhance tumor cell invasiveness and metastasis (9, 11, 12), which would
clearly limit its therapeutic potential. Alternative to this approach is to treat tumors with a
human collagenase. This is the most direct extension of the matrix degradation method
used in the bacterial collagenase study.
Catabolism of extracellular matrix components is generally carried out by members of the
matrix metalloproteinase (MMP) family of enzymes. These endopeptidases cleave nearly
all extracellular matrix components and are thought to be important in matrix remodeling
during development as well as homeostasis (13, 14). Unsurprisingly, these enzymes have
also been found to play a role in various diseases involving matrix modification, such as
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arthritis, fibrosis and cancer metastasis (15, 16). Three soluble MMPs have been found to
have the ability to cleave type I collagen: MMP-1, -8 and -13 (17-19). While all three
enzymes cleave collagen at a single site into approximately ¼ and 34-length fragments,
their collagenase activity is most likely not identical. The activity of these three MMPs
against fibrillar collagen type I has not been directly compared; however, although each
enzyme exhibits activity against collagen types I, II and III, they vary in their relative
rates of activity for these substrates (20-23). In addition to these three MMPs, one other
enzyme has been found to be able to cleave collagen type I: cathepsin K. This enzyme is
responsible for collagen degradation in osteoclasts during bone resorption (24, 25). In
contrast to the MMPs, cathepsin K degrades collagen type I at multiple sites (26). In this
study we directly compare these four collagenases using an in vitro collagen fiber
degradation assay. We assess the ability of the most promising candidates to degrade




All animal experiments were done with the approval of the Institutional Animal Care and
Use Committee (MGH SRAC protocol 2004N000063). Human soft tissue sarcoma
HSTS26T cells were grown in dorsal skinfold chambers in SCID mice as described
previously (27). The entire preparation was done under anesthesia (100 mg ketamine
hydrochloride/10 mg of xylazine per kg body weight intramuscularly) in aseptic
conditions inside the animal colony. Briefly, the back of the mouse was shaved and hair
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removed using hair removal cream. Two symmetrical titanium frames were stitched on to
fix the extended double layer of dorsal skin between the frames. Roughly 15 mm
diameter of skin was removed from one side, leaving the opposite side of the skin,
striated muscle and subcutaneous tissue intact. The fascia was carefully removed and a
cover glass was mounted into the frame. The animals were allowed to recover for at least
one day prior to tumor implantation. Tumors were allowed to grow for at least two weeks
prior to experimentation.
Enzymes
MMP-1 cDNA was purchased from ATCC. MMP-8 cDNA was a kind gift from David
Tarin (University of California, San Diego). MMP-13 cDNA was a kind gift from Carlos
Lopez Otin (University of Oviedo). Cathepsin K cDNA was purchased from Invitrogen
(Carlsbad, CA). The cDNA for all full length enzymes were subcloned into the
mammalian expression vector peakl 3 (kind gift from Brian Seed, Massachusetts General
Hospital). HSTS26T cells were transiently transfected with each collagenase expression
vector using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the
manufacturer's protocol. Twelve hours following transfection, the cells were washed and
incubated with serum free media. Twenty-four hour conditioned media was collected for
the collagenase activity assay. Recombinant bacterial collagenase was purchased from




Conditioned media containing MMP-1, -8 and -13 expressed from HSTS26T cells were
activated with p-aminophenylmercuric acetate (APMA, Sigma, St. Louis, MO). APMA
was dissolved in DMSO at a stock concentration of 20 mM and used to activate MMPs at
a final concentration of 2 mM. Samples were incubated at 370 C for 1 hr and western blot
analysis proceeded immediately afterward.
Recombinant MMPs used for in vivo tumor superfusion were activated with trypsin. A
1:10 volume of 1 mg/ml trypsin (Worthington, Lakewood, NJ) was added to the sample
and incubated at 37°C for 7 minutes. A 1:10 volume of 5 mg/ml soybean trypsin inhibitor
(Worthington, Lakewood, NJ) was then added to the sample to inactivate the trypsin.
Samples were used immediately in experiments. Bacterial collagenase did not require
activation.
Collagenase activity assay
MMP activity was determined using an in vitro collagenolytic activity assay modified
from the method of Johnson-Wint (28, 29). Briefly, type I collagen was purified from rat
tail by solubilization with acetic acid and subsequently acetylated with [14C] acetic
anhydride. Fibrils were allowed to form from the radiolabeled collagen and were dried
onto wells of a 96-well plate, forming a thin film. Conditioned media samples were added
to wells and incubated at 370 C for 2.5 hours. The supernatants containing soluble
radiolabeled collagen (from cleavage) were transferred to scintillation vials and counted
in a Beckman model LS-3801 scintillation counter. Bacterial collagenase was used as a
103
control to cleave all the radiolabeled collagen in select wells. One unit of activity
corresponds to degradation of 10% of the collagen in 2.5 hrs at 370C.
Second harmonic generation imaging
Imaging of second harmonic generation (SHG) in dorsal chamber tumors was performed
with a custom-built multiphoton laser scanning microscope (30) using a 20X/0.5NA
objective lens. Excitation was at 880 nm and SHG was detected via a 435DF30 emission
filter with a high pass 475 dichroic. Three dimensional image stacks were obtained of the
top 130 gm from the surface of the tumor (27 images of 5 gtm thickness). Six to ten
image stacks were obtained to create a montage covering the entire tumor or a significant
portion of it. The total SHG signal intensity in each stack was measured by image
analysis (ImageJ) and the mean intensity for each individual tumor calculated.
Multiphoton fluorescence recovery after photobleaching
The diffusion coefficient of2x10 6 molecular weight dextran was measured in dorsal
chamber tumors using multiphoton fluorescence recover after photobleaching
(MPFRAP). A custom-built multiphoton microscope (30) was adapted for MPFRAP
based on a previous design (31). One half microliter of FITC-labeled dextran (Sigma, St.
Louis, MO) was injected at a concentration of 2 mg/ml at a depth of 200 gtm below the
surface of the tumor. Injections were performed using glass micropipettes that were
pulled to obtain a 20 glm inner diameter tip (27). Injections were performed at nearly
constant flow rate over 2-3 minutes.
104
MPFRAP was performed approximately 30 minutes after injection. The laser was set at
800 nm and a 40X/0.75 NA objective lens was used with a 525/100 filter between 405
and 605 high pass dichroics. The multiphoton laser was focused on locations in the
extracellular space 40-70 gtm below the surface of the tumor. During each
bleach/recovery cycle, the sample was bleached with a 160 gts pulse train of light,
followed by an -40 ms recovery monitored in 40 gts time bins. The length of the bleach
and the time bins for monitoring recovery were chosen to avoid significant error due to
diffusion during these two time periods. Based on the analysis of Brown et al. (31), the
systematic error in the detected fluorescence intensity due to diffusion during the bleach
pulse and over the course of recovery is -1.05(At/TD) where At is the length of the bleach
pulse or monitoring time bin and rD is the time constant for diffusive recovery. The
characteristic fluorescence recovery time of2x10 6 molecular weight dextran in vivo was
found to be -10 ms. Thus, a bleaching pulse length of 160 is is short enough to avoid
significant diffusion during the bleach pulse (error of--1.68%) and a monitoring time bin
of 40 ts is short enough to accurately monitor the recovery (error of -0.42%).
The monitoring power was chosen such that photobleaching did not occur. The bleaching
power was chosen such that excitation saturation did not occur. Each bleach/recovery
cycle was repeated 500 to 1000 times for a given spot/measurement. Approximately 10 to
20 measurements were taken for each individual tumor. Data acquisition typically lasted
2 hrs. The recovery curves were fit to the following equation, derived in Brown et al.
(31), which gives the time-dependent detected fluorescence signal due to diffusion into
the focal volume:
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F(t) is the time-dependent fluorescence signal, Fo is the prebleach equilibrium
fluorescence signal, m is the number of photons required to generate a fluorescence
photon, 3 is the bleach depth parameter, b is the number of photons absorbed in a
bleaching event, t is the time, R is the square ratio of the 1/e2 beam dimensions (wz2/w 2)
and 7TD is the characteristic radial diffusion time of the fluorophore, defined as wf/8D,
where D is the diffusion coefficient. The beam dimensions for for the objective lens at a
wavelength of 840 nm was calculated theoretically, with wz = 1.837 x 10- m and wr =
3.221 x 10-7 m.
Oncolytic virus
The oncolytic HSV-1 vector MGH2 (ICP6-, y34.5-, eGFP+) was obtained from E.
Antonio Chiocca and Yoshi Saeki (The Ohio State University). MGH2 stocks were
propagated in E 11 cells (gift from Yoshi Saeki). Infected cells were pelleted, resuspended
in 1 ml of HBSS and subjected to 3 freeze/thaw cycles in a dry ice/ethanol bath with 1
minute of vortexing in between. Lysed cells were spun down at 3500 rpm for 15 minutes.
The supernatants were filtered through a cell strainer and a 0.45 Im syringe filter. The
filtered supernatant was layered over 5 ml of 25% sucrose (in PBS) in a 38.5 ml
centrifuge tube. This was topped off with HBSS and spun down at 20,000 rpm for 3
hours at 40C. The supernatant was aspirated and the viral pellet was covered with 200 1il
HBSS and incubated overnight at 40C. The virus was resuspended the following day and
stored at -800 C. The virus was titered using HSTS26T cells.
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Flank tumor growth delay
HSTS26T tumors were implanted subcutaneously in the leg of SCID mice and allowed to
reach 60 mm3 average volume. Mice were then randomized into 3 groups (6-7 animals
per group) and given 10 il intratumoral injections of either 2.5 x 105 t.u. of MGH2 in
trypsin/trypsin inhibitor solution; 2.5 x 105 t.u. of MGH2 with 1.0 jtg activated
recombinant MMP-1; or 2.5 x 105 t.u. of MGH2 with 1.0 gtg activated recombinant
MMP-8. A second similar injection was performed two days later. All injections were 15
jtl total volume. Tumor volume was measured every 3-4 days and calculated as volume =
7rAB 2/6, where A and B are maximum and minimum diameters, respectively.
Results
Screening human collagenases
Several human enzymes have been identified in the literature as having the ability to
cleave collagen type I based on in vitro assays: MMP-1, MMP-8, MMP-13 and cathepsin
K. In order to assess which would be most promising for our specific application -
degradation of fibrillar collagen in a solid tumor - we first directly compared each
enzyme in an in vitro assay. Each enzyme was expressed in human soft tissue sarcoma
HSTS26T cells and collected in the conditioned media. Expression was confirmed by
western blot. Each enzyme was activated and then incubated with reconstituted collagen
fibrils that had been [14 C] radiolabeled. The amount of degradation was assessed by
measuring the amount of cleaved collagen in the supernatant after 2.5 hrs at 370 C. MMP-
1 and MMP-8 showed significant collagenase activity relative to the control (Fig. 4.1). In
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contrast, MMP-13 and cathepsin K showed no collagenase activity. Previous studies have
shown that the collagenase activity of cathepsin K is highly pH-dependent, with maximal
activity in slightly acidic conditions (25). Other studies have shown that the activity of
cathepsin K is enhanced by the formation of a complex with chondroitin sulfate (32, 33).
Therefore, the collagenase activity assays for cathepsin K were repeated at a range of pH
(4.0 - 8.0), in the presence and absence of chondroiton sulfate and with various methods
of activation. However, significant activity was not observed in any sample. Based on
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Figure 4.1. Collagenase activity of various human enzymes. Human collagenases were
expressed in HSTS26T cells and collected in the conditioned media. Samples were
activated with the appropriate agent and incubated with radiolabeled collagen fibrils. The





Collagen degradation in vivo with MMP-1 and MMP-8
Next we sought to determine the extent of collagen degradation in vivo. Purified
recombinant MMP-1 and MMP-8 were activated with trypsin and superfused on the
surface of HSTS26T tumors grown orthotopically in the dorsal chamber of SCID mice.
Fibrillar collagen I was monitored with multiphoton imaging of second harmonic
generation (SHG). SHG signal emanates from a highly fibrillar subfraction of collagen
has been found to correlate with total collagen content in vivo (5). Total SHG intensity in
tumors was measured before treatment and 12, 36 and 84 hours after superfusion of
MMPs (Fig. 4.2). Over a period of- 4 days, the fibrillar collagen content in untreated
tumors did not significantly change. SHG intensity decreased significantly by 12 hours
following MMP-1 superfusion but not MMP-8. The change in collagen content with
MMP-1 was maintained at 84 hrs post-treatment.
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Figure 4.2. Effect of human collagenase superfusion on second harmonic generation
intensity over a long time period. 10 itl of activated MMP-1 and -8 (0.1 Ig/Ipl) were
superfused on HSTS26T tumors grown in the dorsal skinfold chamber of SCID mice.
SHG throughout the tumor was imaged at various time points before and after
superfusion. Mean normalized intensities and standard errors are shown. At 12, 36 and 84
hours, MMP-1, but not MMP-8, induces a significant decrease relative to control tumors
(P < 0.05).
Since the degradation of collagen with MMP-1 treatment has already occurred by 12
hours, we sought to examine the kinetics of this degradation by measuring collagen
content during the first several hours following superfusion. Since the half life of MMPs
in tumors is most likely on the order of hours, this is a relevant time scale for observation.
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hours following MMP superfusion. The same region of the tumor was imaged every 5
minutes (Fig. 4.3). As expected, no change in collagen was observed in control tumors
and with recombinant MMP-8 application. MMP-1 superfusion caused a small but
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Figure 4.3. Effect of human collagenase superfusion on tumor second harmonic
generation intensity over a short time period. 10 #l of active MMPs was superfused on
HSTS26T tumors grown in the dorsal skinfold chamber of SCID mice. A 250 im x 200
Im x 130 /im area of the tumor was imaged every 5 minutes for ~100 minutes and the
SHG intensity in a maximum intensity z-projection was measured. The normalized mean
intensities and standard errors are shown. At 100 minutes, MMP- 1 results in a small but
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Bacterial collagenase had previously been shown to degrade collagen, improve diffusion
and enhance the distribution and efficacy of an intratumorally injected therapeutic (5, 34-
36). Thus, it serves as a reference for gauging the extent of collagen degradation
necessary to improve the transport and efficacy of therapeutics. With this in mind we
assessed the ability of bacterial collagenase to degrade collagen in an identical assay. A
nearly equimolar amount of bacterial collagenase led to a significant decrease in collagen
within 100 minutes (Fig. 4.4). The effect was significantly more dramatic than with
MMP-1 and was dose dependent. We should note that while purified bacterial
collagenase is relatively easy to obtain in large quantities, recombinant MMPs are much
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Effect of recombinant MMPs on interstitial diffusion
While theses result show that the effect of MMP-l and MMP-8 on tumor collagen at this
dose are subtle at best, the possibility exists that such subtle changes may lead to
significant improvements in interstitial transport. Indeed, chronic relaxin treatment of
tumors did not alter total SHG signal, but did alter the length of collagen fibers and
consequently the diffusion of tracer particles (5). To determine what effect these
recombinant MMPs have on tumor interstitial transport we measured the diffusion
coefficient of 1x106 molecular weight dextran with multiphoton fluorescence recovery
after photobleaching (MPFRAP). These dextran tracer particles have an estimated
hydrodynamic diameter of -40 nm, making them relevant for the study of the transport of
macromolecules such as antibodies (12 nm diameter) and viral vectors (20-150 nm
diameter). We found that the diffusion coefficient is unchanged in MMP-1 and MMP-8
treated tumors (Fig. 4.5). As expected from the dramatic effects on tumor collagen,
treatment with bacterial collagenase leads to a significant increase in the diffusion
coefficient (P < 0.05). Thus, it appears that while application of 0.1 #g/p/l recombinant
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Figure 4.4. Effect of bacterial collagenase superfusion on tumor SHG intensity over a
short time period. 10 l of bacterial collagenase was superfused on HSTS26T tumors
grown in the dorsal skinfold chamber of SCID mice. SHG signal was imaged as before.
The normalized mean intensities and standard errors are shown. At 100 minutes, both
concentrations of bacterial collagenase resulted in a significant decrease in collagen
relative to control (P < 0.05 in both cases).
MMP-1 to tumors can modify the tumor collagen, the effect is not dramatic enough to
significantly alter diffusive transport.
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Effect of MMPs on oncolytic HSV treatment of tumors
Finally, we also checked if co-injection of MMP-l or MMP-8 can enhance the efficacy of
the oncolytic HSV vector MGH2 as bacterial collagenase can. While collagen content
was not dramatically decreased and the diffusion of tracer particles was not affected,
perhaps some other alteration occurred that could improve viral distribution. Ultimately
we are interested in developing methods to improve oncolytic viral therapy. To that end,
HSTS26T tumors were grown subcutaneously in the leg of SCID mice. At -60 mm3 they
were treated with an injection of either 2.5x106 t.u. of MGH2 alone, MGH2 with 1.0 tg
MMP-1 or MGH2 with 1.0 Ig MMP-8. A similar injection was repeated two days later.
The tumor volume was monitored over several weeks. MMP-1 and MMP-8 co-injection
did not enhance the efficacy of MGH2 therapy (Fig. 4.6).
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Figure 4.5. Effect of collagenase superfusion on diffusion. The effective diffusion
coefficient of lx106 molecular weight dextran in HSTS26T tumors grown in the dorsal
chamber was measured by MPFRAP. (A) Mean diffusion coefficients with standard
errors. N = 5-6 for each treatment. Bacterial collagenase treatment causes a significant
increase in the diffusion coefficient relative to control (P < 0.05). MMP-1 and MMP-8
application does not alter the effective diffusion coefficient. (B) Individual diffusion
coefficient measurements for each tumor (black dots), mean for each tumor (red lines and
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Figure 4.6. Effect of recombinant MMP-1 and MMP-8 on oncolytic HSV treatment.
HSTS26T tumors were grown subcutaneously in the leg of SCID mice and treated with
two intratumor injections of either 2.5x10 6 t.u. of MGH2 alone or in combination with
1.0 pg recombinant MMP-1 or MMP-8. (A) Mean tumor volume of treated and control




We have found that while all four human enzymes we screened are reported to have
activity against collagen type I, only MMP-1 and -8 showed significant activity in our
fibril assay. It is still uncertain why MMP-13 exhibited almost no collagenase activity
relative to the other MMPs. MMP-13 is enzymatically similar to the other two enzymes:
it has a similar domain structure and cleaves collagen type I at the same peptide bond
(Gly775-Ile776). While MMP-13 does not share much sequence homology to MMP-1 (18),
neither does MMP-8 (19). One possibility for why no activity was observed is that the
true substrate for MMP-13 in vivo is type II collagen, rather than type I. MMP-13 has
significantly greater activity against collagen type II relative to type I (21) and is better at
degrading collagen type II than either MMP-1 or MMP-8 (37, 38). Furthermore, MMP-
13 has been found to play a role in collagen II degradation in osteoarthritis and
rheumatoid arthritis (39-41). A second possibility is that the mechanism of MMP-13
activation differs from its counterparts. Indeed it has been shown that MMP-13 can be
activated by a proteolytic cascade that includes MMP-14 and MMP-2 (42), while MMP-1
and -8 have not been found to be activated in such a manner. APMA was chosen as the in
vitro activating agent for all three enzymes since it has been used in numerous
117
given as the time for the tumor to grow to ten times the size at treatment. There is no
significant difference in the growth delay between tumors treated with virus alone or with
recombinant MMPs.
biochemical assays for each. Perhaps this agent is sufficient for activating MMP-1 and -8
but does not maximally activate MMP-13.
The low activity of cathepsin K is less surprising. While it has been found that cathepsin
K is a very potent collagenase - on par with bacterial collagenase - these activity assays
were performed at pH 5.5, the pH in osteoclasts where cathepsin K degrades collagen in
physiological settings (26). As discussed above, the collagenase activity of cathepsin K
varies with pH and is optimal in acidic conditions (25). This can be partially explained by
the fact that autolysis occurs readily and the stability of cathepsin K at 370 C is low at
neutral pH: in one half hour nearly 90% of activity is lost. Thus, while we adjusted the
pH of samples to 6.0 and below in our activity assays - and found no activity - the
enzyme may have autodegraded while in the media, which can be neutral or slightly
basic. Indeed, our western blots of the conditioned media samples showed multiple
bands, suggesting that some of the enzyme had gone through autodegradation. In
addition, studies have shown that while chondroiton sulfate and keratin sulfate can
enhance collagenase activity by forming a complex with cathepsin K, the other GAGs
such as dermatin sulfate and heparan sulfate can effectively inhibit activity by binding
and preventing the interaction of the enzyme with the "productive" GAGs (33). We may
have observed no activity in the presence of chondroiton sulfate in our assays due to the
binding of cathepsin K to other GAGs while in the media. In total, this suggests that it
may still be possible to use cathepsin K to degrade collagen in tumors even while little
activity was observed in our assays with conditioned media. Tumors can be slightly
acidic and contain various soluble GAGs. Purified, recombinant cathepsin K can even be
complexed with chondroiton sulfate before being applied to tumors. However, the
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intricate nature of activation, inhibition and degradation of this enzyme suggests that their
use as collagenases in vivo may require substantial optimization.
In our in vivo assays, MMP-1 and MMP-8 were not able to replicate our previous
findings with bacterial collagenase. Total collagen levels in tumors - as assessed by SHG
signal - decreased only slightly with recombinant MMP-1 application and not at all with
MMP-8. Neither MMP affected diffusion or the efficacy of an oncolytic HSV vector.
One possible reason may be the nature of collagen cleavage for each type of enzyme.
Bacterial collagenase is not a single enzyme, but rather a collection of seven distinct
enzymes (43-45). It is believed that there are two main gene products - the true
collagenases - and that the lower molecular weight enzymes are proteolytic cleavage
products of these full length enzymes (46). Importantly, these lower molecular weight
enzymes have gelatinase activity and bacterial collagenase can cleave collagen at
multiple sites into small peptides. When we have degraded collagen molecules with
bacterial collagenase, we find that collagen is converted into peptide fragments that are
all smaller than 10 kDa. In contrast, MMP-1 and -8 cleaves collagen at a single site into
two relatively large fragments (47, 48). While both MMPs contain some gelatinase
activity, it is one to two orders of magnitude less than the collagenase activity (21). Thus
in and of itself, MMP-l and -8 may not be able to solubilize fibrillar collagen as bacterial
collagenase does. Perhaps the breakdown of collagen into small peptides facilitates its
clearance from the interstitium and is key to the improvements in transport seen with
bacterial collagenase.
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An alternative hypothesis is that the dose used in these studies is insufficient to effect the
changes in collagen needed to improve interstitial diffusion. In our in vitro collagenase
activity assay, the activity of MMPs is less than that of bacterial collagenase on a per
molar basis. This suggests that increasing the dose may be necessary to see an equivalent
improvement in collagen degradation and diffusive transport in vivo. Due to the difficulty
in producing and purifying human proteins, increasing the dose of recombinant proteins
from that used in this study is prohibitively expensive. Expression of these collagenases
in the tumor cells, themselves, by stable transfection offers another option that would
effectively increase the dose and have several other advantages. First, this would provide
chronic rather than acute delivery of the enzymes to the tumor; collagenase would be
delivered throughout the course of tumor progression. Second, this ensures that the
collagenase is delivered to all parts of the tumor, since it will be expressed by all tumor
cells. Finally, this would provide proof of principle for genetic delivery of a human
collagenase in a therapeutic setting, such as with an oncolytic viral vector.
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Chapter 5: Effect of MMP-1 and MMP-8 Expression in Tumors
Portions of the chapter have been taken from:
W. Mok, Y. Boucher and R.K. Jain, "Matrix Metalloproteinase-1 and -8 Improve the Distribution
and Efficacy of an Oncolytic Virus." In press, Cancer Research
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Introduction
There are several methods by which collagenases can be delivered to the tumor to
achieve matrix degradation and improve interstitial transport. In the previous two
chapters, purified, recombinant collagenases have been directly applied to, or injected
into, tumors. While this has been a successful strategy with bacterial collagenase (1), our
work with human collagenases in the preceding chapter highlights one of the limitations
of this method: recombinant enzymes can be difficult and expensive to purify in large
amounts. This drawback prevented us from testing higher doses of MMP-1 and -8 - both
of which are less potent collagenases than bacterial collagenase - and perhaps realizing
more dramatic effects on tumor collagen and improvement in transport.
An alternative strategy to delivering the protein is to deliver its genetic precursor, the
cDNA. Delivery of genetic material via non-viral vectors such as liposomes is well suited
for cancer therapy since its large scale production is cost-effective and it has shown
biological success both in vitro and in vivo (2). The other main class of genetic delivery
vehicles includes viral vectors. This thesis focuses on improving the transport of
oncolytic viral vectors. These viral vectors are unique in that they can serve as both
genetic delivery vectors and as therapeutics, themselves, since they lyse cancer cells (3).
Recombinant oncolytic viruses can be developed which contain an expression cassette for
a human collagenase. In theory, tumor cells infected by such an oncolytic vector will
produce the collagenase, as well as viral proteins. This collagenase will be secreted from
the infected cell and released upon cell lysis. The enzymes can diffuse throughout the
interstitium and degrade collagen, potentially improving the spread of the progeny virus.
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One main advantage of this approach over the use of recombinant enzymes is that tumor
cells infected by progeny virus continue to express the transgene. Thus, this method
provides chronic, rather than acute, delivery of collagenase to the tumor.
In order to provide proof of principle that genetic delivery of human collagenases to
tumors is a suitable method to alter their interstitial matrix, an experimental model is
developed whereby tumor cells are stably transfected with either MMP-1 or MMP-8 and
tumors are grown in mice. This model represents the best case scenario for gene transfer
of MMPs, as all tumor cells will be expressing the enzyme throughout the entire course
of tumor development.
MMP-1 and -8 have the ability to degrade multiple fibrillar collagens - not just type I
collagen - as well as various glycoproteins and proteoglycans (4). Thus, they have the
potential to significantly alter the composition and structure of the tumor extracellular
matrix, especially when delivered chronically such as via overexpression in cells.
Therefore, in the present chapter we characterize the effect of MMP expression on the
main structural components of the extracellular matrix (i.e. collagen I, hyaluronic acid
and sulfated GAGs). Since these matrix components are known to regulate both diffusive
and convective transport in tissue, we measure both the effective diffusion coefficient of
tracer particles and the hydraulic conductivity of these tumors. Both diffusion and
convection can limit the transport and distribution of cancer therapeutics. As described
earlier, our lab has shown that the tumor ECM can significantly hinder the interstitial
diffusion of macromolecules (5, 6). In Chapter 3, we provided evidence that ECM
structures can impede the convection of viral particles into the tumor during infusion (1).
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Here we characterize the effect of MMP-1 and -8 expression on the tumor ECM




All animal experiments were done with the approval of the Institutional Animal Care and
Use Committee (MGH SRAC protocol 2004N000063). Human soft tissue sarcoma
HSTS26T cells and transfected clones were grown in dorsal skinfold chambers in SCID
mice as described previously (7). The entire preparation was done under anesthesia (100
mg ketamine hydrochloride/10 mg of xylazine per kg body weight intramuscularly) in
aseptic conditions inside the animal colony. Briefly, the back of the mouse was shaved
and hair removed using hair removal cream. Two symmetrical titanium frames were
stitched on to fix the extended double layer of dorsal skin between the frames. Roughly
15 mm diameter of skin was removed from one side, leaving the opposite side of the skin,
striated muscle and subcutaneous tissue intact. The fascia was carefully removed and a
cover glass was mounted into the frame. The animals were allowed to recover for at least
one day prior to tumor implantation. Tumors were allowed to grow for at least two weeks
prior to experimentation.
Plasmid construction and stable transfections
A retroviral transfection system was used to generate stable MMP-1 and MMP-8
transfectants. The cDNA coding for human MMP-1 was purchased from ATCC and the
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cDNA coding for human MMP-8 was a gift from David Tarin (University of California,
San Diego). The full length cDNAs were subcloned into the retroviral vector pBMN-I-
GFP (Garry Nolan, Stanford University). The vector contains an IRES allowing for
expression of enhanced green fluorescence protein (EGFP).
Retroviral vectors for the stable transfections were packaged according to the following
protocol, described previously (8). 80-90% confluent T75 flasks of 293ET packaging
cells were transiently transfected with each BMN vector (15 pg) in combination with
plasmids expressing vesicular stomatitis virus glycoprotein (VSVG, 5 Ag) and gag/pol (7
pig). After overnight incubation, the 293ET cells were washed three times with PBS and
then 10 mL of fresh media was added. The following day the conditioned media
containing retrovirus was collected and fresh media added to the flask. The conditioned
media was spun down to remove any cell debris and passed through a 0.45 AM filter
(Whatman, Brentford, UK). Subconfluent HSTS26T cells were incubated with the
conditioned media containing retrovirus. The conditioned media from the 293ET
packaging cells were collected the following two days and transduction repeated. Clones
with stable transduction were isolated using fluorescence activated cell sorting.
Expression of MMPs was confirmed with western blot.
Protein isolation
Tumors were grown subcutaneously in the leg of SCID mice. At an appropriate size,
tumors were harvested and immediately snap frozen in liquid nitrogen and stored at -
800C. Tissue was homogenized in 100 AL RIPA buffer. Samples were kept on ice for 30
minutes and then spun down at 14,000 g for 20 minutes to pellet the cell debris. The
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supernatant containing tissue protein was collected. Protein concentration was measured
using the Bradford assay (BioRad Laboratories, Hercules, CA) according to the
manufacturer's instructions. Pre-diluted BSA (Pierce Biotechnology, Rockford, IL) was
used as a protein standard. Protein samples were stored at -800C prior to use in activity
assays and western blots.
Western blot
Loading buffer containing fl-mercaptoethanol was added to the protein samples and they
were boiled at 1000C for 5 minutes. Samples were loaded into a 10% Bis-Tris gel
(Invitrogen, Carlsbad, CA) and run at 150V for - 1 hr. The proteins were transferred to a
nitrocellulose membrane. The transfer was performed at 30V for 1 hr at room
temperature. The membrane was washed with TBST for 10 minutes. The membrane was
placed in 20 mL of blocking buffer (TBST with 5% milk) and incubated at room
temperature for 3 hrs with gently shaking. The membrane was incubated with primary
antibody at 40C overnight with gentle shaking. Polyclonal antibodies AB806 and AB8115
(Millipore, Billerica, MA) were used at a dilution of 1:2,500 for detection of MMP-1 and
MMP-8, respectively. Polyclonal antibody EL 2900 (for cleaved collagen I) was a gift
from Eunice Lee (Shriners Hospital for Children, Canada) and was used at a
concentration of 4 #tg/ml (1:500). The following day, the membrane was washed 3x for
10 minutes with TBST with vigorous shaking. The membrane was then incubated for 1 hr
at room temperature with an HRP-conjugated secondary antibody (Amersham,
Buckinghamshire, UK). The membrane was washed again with TBST with vigorous
shaking and proteins detected using the ECL or ECL Plus kit (Amersham,
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Buckinghamshire, UK). Membranes were stripped by incubating with stripping buffer
(Pierce Biotechnology, Rockford, IL) at 370C and beta actin detected with a polyclonal
antibody (Santa Cruz Biotechnology, Santa Cruz, CA).
Collagenase activity assay
MMP activity was determined using an in vitro collagenolytic activity assay modified
from the method of Johnson-Wint (9, 10). Briefly, type I collagen was purified from rat
tail by solubilization with acetic acid and subsequently acetylated with [14C] acetic
anhydride. Fibrils were allowed to form from the radiolabeled collagen and were dried
onto wells of a 96-well plate, forming a thin film. Tumor lysate samples were added to
wells and incubated at 37°C for 2.5 hours. To activate the MMPs, a 1:10 volume of 1
mg/ml trypsin (Worthington, Lakewood, NJ) was added to the sample and incubated at
37°C for 7 minutes. A 1:10 volume of 5 mg/ml soybean trypsin inhibitor (Worthington,
Lakewood, NJ) was then added to the sample to inactivate the trypsin. Samples were
immediately added to wells containing collagen. The supernatants containing soluble
radiolabeled collagen (from cleavage) were transferred to scintillation vials and counted
in a Beckman model LS-3801 scintillation counter. Bacterial collagense was used as a
control to cleave all the radiolabeled collagen in select wells. Bovine corneal collagense
was used as the enzyme control in inhibitor assays. One unit of activity corresponds to
degradation of 10% of the collagen in 2.5 hrs at 370C.
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SHG imaging and quantification
Imaging of second harmonic generation (SHG) in dorsal chamber tumors was performed
with a custom-built multiphoton laser scanning microscope (11) using a 20X/0.5NA
objective lens. Excitation was at 880 nm and SHG was detected via a 435DF30 emission
filter with a high pass 475 dichroic. Three dimensional image stacks were obtained of the
top 130 jim from the surface of the tumor (27 images of 5 gm thickness). Six to ten
image stacks were obtained to create a montage covering the entire tumor or a significant
portion of it. The total SHG signal intensity in each stack was measured by image
analysis (ImageJ) and the mean intensity for each individual tumor calculated.
Histology
Tumor tissue was harvested, fixed in 4% paraformaldehyde for 3 hrs and incubated in
PBS overnight. Tissue was embedded in either paraffin or optimal cutting temperature
compound (Tissue-Tek). 20 tm thickness sections were cut.
Collagen I staining of frozen sections and quantification was performed as described
previously (6). Rabbit polyclonal antibody against collagen I (LF-67) was obtained from
Larry Fisher (National Institute of Dental Research) and used at a dilution of 1:200. A
Cy3-conjugated secondary antibody (Jackson Immunoresearch, West Grove, PA) was
used. Cell nuclei were stained with DAPI. For quantification of the fraction of tissue
occupied by collagen I staining, images were taken with a multiphoton microscope (11).
Using 800 nm light with a 20X/0.5 numerical aperture lens, image stacks (10 images)
were obtained of the stained sections. A 625/75 filter was used for Cy3 imaging and
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435/40 for DAPI, with a 570 dichroic. A maximum intensity projection of the image
stacks was taken to generate a single image, thereby ensuring that each pixel value
represents the best colocalization of the excitation volume with the slice. Ten images
were taken per section in random locations and 7 sections were analyzed for each group.
Using a series of threshold pixel values the fraction of tissue section containing nuclear,
non-specific and specific collagen staining was determined.
HSV-1 and HA binding protein (HABP) staining was performed on paraffin sections.
Tissue sections were deparaffinized and hydrated. Sections were permeabilized with 3%
hydrogen peroxide for 5 minutes, washed three times in PBS with 3% BSA and blocked
for 1 hr with 3% BSA/PBS. The tissue was incubated with a polyclonal anti-HSV-1
antibody (Dako, Glostrup, Denmark) at a dilution of 1:8000 for 30 minutes at room
temperature. For HA staining tissues were incubated with biotinylated HA binding
protein (EMD Chemical, Madison, WI) at a dilution of 1:150. Sections were incubated
with peroxidase-conjugated streptavidin and DAB chromogen was used as substrate
(Dako, Glostrup, Denmark). For quantification of HA staining, 8 random images were
taken per section with a 20X objective lens with an inverted microscope (Olympus,
Center Valley, PA). Image analysis was performed using a macro developed in Adobe
Photoshop. The brown pseudocolor was selected and thresholded using the color
selection function and the mean brown pixel count for each section was measured. For
HSV staining, individual images were taken with a 10X objective lens to create a
montage of the entire tumor. The contrast was insufficient for image analysis using the
macro. Instead, a square grid with 100 /m length grid boxes was overlayed on the images
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and grid boxes containing brown staining were counted. In both cases, 6-7 tissues
sections were analyzed per tumor type.
Construction of recombinant HSV vectors
Recombinant oncolytic HSV-1 vectors expressing MMP-1 and MMP-8 were generated
using the HSVQuik system (12) (Fig. 5.1). A brief description of the protocol follows,
while a more detailed version can be found in the manuscript. The MMP-1 and MMP-8
cDNA were subcloned into the pcDNA3.1 mammalian expression vector (Invitrogen,
Carlsbad, CA). The expression cassette containing the CMV promoter, MMP cDNA and
polyA was amplified by PCR and subcloned into the pTransfer shuttle plasmid. The
pTransfer multiple cloning site is flanked by FRT and loxP sites to mediate homologous
recombination. pTransfer-MMP-x plasmids were electroporated together with an FLP-
expressing helper plasmid into bacteria carrying fflSVQuik-1 BAC plasmid. The
fHSVQuik-1 BAC was cloned from the MGH1 genome, which contains deletions in both
copies of the y34.5 gene and a lacZ insertion at the UL39 locus. It contains two
recombination sequences: FRT sites to facilitate insertion of transgene cassettes into the
UL39 locus and loxP sites for later removal ofprokaryotic plasmid sequences from the
vector genome. It also contains the EGFP coding sequence to visualize infected cells and
an RFP expression cassette in the middle of the BAC backbone to monitor the presence
of the BAC sequences in the vector genome. Approximately 100 ng of each pTransfer
plasmid and the FLP-expressing helper plasmid were used. An electrical pulse was
applied using the Gene Pulser II device with a setting of 1.8 kV, 200 (9, 25 #F.
Cointegrants of the pTransfer-MMP-x and fflsvQuik-1 fused at the FRT sites (fflsvQ1-
133
MMP-x) were obtained by selection with chloramphenicaol and ampicillin (both 15
Ag/ml). BAC DNA was prepared by conventional alkaline method and candidate clones
were screened with HindIII restriction digest patterns.
The ffIsvQ1-MMP-x has the transgene cassette inserted at the UL39 locus and two
unidirectional loxP sites now flanking all of the prokaryotic plasmid backbones and the
RFP marker gene. ffIsvQ1-MMP-x (2 jg) and a Cre-expressing helper plasmid (0.5 jg)
were cotransfected into Vero cells using LipfectAMINE reagent (Invitrogen, Carlsbad,
CA). Transfected cells were harvested and freeze/thawed to recover packaged
recombinant virus. Vero cells were infected with serially diluted samples of the vector
supernatant and individual recombinant HSV vectors were propagated. The expression of
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Figure 5.1. Schematic strategy for generation of recombinant oncolytic HSV vectors.
fHsvQuik-1 is a BAC plasmid developed from the genome of MGH1, an oncolytic HSV
vector containing deletions in both copies of the y34. 5 gene and a lacZ insertion at the
UL39 locus. Co-electroporation of fHsvQuik-l with pTransfer vectors containing the
gene of interest and an FLP-expressing plasmid result in insertion of the gene of interest
in the UL39 locus, generating fH-IsvQl-x. Co-transfection of Vero cells with fHsvQ1-x
and a Cre-expressing plasmid results in removal of the prokaryotic plasmid backbones
and packaging of recombinant virus (rHsvQ1 -x).
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Tumor growth delay
HSTS26T tumors (or transfected variants) were implanted subcutaneously in the leg of
SCID mice and allowed to reach 60 mm3 average volume. Mice were then randomized
into separate groups (6-7 animals per group) and given 10 ýil intratumoral injections of
either 2.5 x 106 t.u. of oncotyic HSV in PBS or PBS alone. A second similar injection
was performed two days later. Tumor volume was measured every 3-4 days and
calculated as volume = 7tAB 2/6, where A and B are the maximum and minimum
diameters, respectively. The time to reach 10 times the volume at treatment was
calculated for each tumor.
Multiphoton fluorescence recovery after photobleaching
The diffusion coefficient of 2x10 6 molecular weight dextran was measured in dorsal
chamber tumors using multiphoton fluorescence recover after photobleaching
(MPFRAP). A custom-built multiphoton microscope (11) was adapted for MPFRAP
based on a previous design (13). One half microliter of tetramethylrhodamine-labeled
dextran (Invitrogen, Carlsbad, CA) was injected at a concentration of 2 mg/ml at a depth
of 200 [tm below the surface of the tumor. Injections were performed using glass
micropipettes that were pulled to obtain a 20 gpm inner diameter tip (6). Injections were
performed at nearly constant flow rate over 2-3 minutes.
MPFRAP was performed approximately 30 minutes after injection. The laser was set at
800 nm and a 40X/0.75 NA objective lens was used with a 525/100 filter between 405
and 605 high pass dichroics. The multiphoton laser was focused on locations in the
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extracellular space 40-70 gLm below the surface of the tumor. During each
bleach/recovery cycle, the sample was bleached with a 160 jts pulse train of light,
followed by an -40 ms recovery monitored in 40 gs time bins. The length of the bleach
and the time bins for monitoring recovery were chosen to avoid significant error due to
diffusion during these two time periods. Based on the analysis of Brown et al. (13), the
systematic error in the detected fluorescence intensity due to diffusion during the bleach
pulse and over the course of recovery is -1.05(At/zD) where At is the length of the bleach
pulse or monitoring time bin and TD is the time constant for diffusive recovery. The
characteristic fluorescence recovery time of2x106 molecular weight dextran in vivo was
found to be -10 ms. Thus, a bleaching pulse length of 160 gts is short enough to avoid
significant diffusion during the bleach pulse (error of-1.68%) and a monitoring time bin
of 40 jis is short enough to accurately monitor the recovery (error of 0.42%).
The monitoring power was chosen such that photobleaching did not occur. The bleaching
power was chosen such that excitation saturation did not occur. Each bleach/recovery
cycle was repeated 500 to 1000 times for a given spot/measurement. Approximately 10 to
20 measurements were taken for each individual tumor. Data acquisition typically lasted
2 hrs. The recovery curves were fit to the following equation, derived in Brown et al.,
which gives the time-dependent detected fluorescence signal due to diffusion into the
focal volume:
Sm 3/ 2 (-fl)" 1 1
F(t) n=O n! (m+bn + (bnmt/rD) m+bn+(bnmt/RTD)
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F(t) is the time-dependent fluorescence signal, Fo is the prebleach equilibrium
fluorescence signal, m is the number of photons required to generate a fluorescence
photon, f is the bleach depth parameter, b is the number of photons absorbed in a
bleaching event, t is the time, R is the square ratio of the 1/e2 beam dimensions (wz2/i2)
and rD is the characteristic radial diffusion time of the fluorophore, defined as w 2/8D,
where D is the diffusion coefficient. The beam dimensions for for the objective lens at a
wavelength of 840 nm was calculated theoretically, with w, = 1.929 x 10-6 m and w =
3.382 x 10-7 m.
Hydraulic conductivity
Measurements were performed using an apparatus based on one designed previously by
Swabb et al. (14). Discs of 3 mm diameter and 1 mm thickness were cut from tumor
tissue. The tissue was ensured grossly free of necrosis and hemorrhage. The tissue was
placed in a tissue clamp and secured in place on both sides with a 3mm disc of polyester
mesh (90 Am thickness, 80 /m mesh opening, 39% open area, Spectrum Laboratories,
Rancho Dominguez, CA). Both sides of the tissue in the clamp were filled with fetal
bovine serum. An o-ring sealed the interior of the clamp to prevent leakage of fluid. The
inlet and outlet of the clamps were connected to polyethylene tubing with an inner
diameter of 0.58 mm. The tubing leads to head tanks, which were filled with water. A
pressure drop was established by adjusting the height of the inlet and outlet head tanks,
and the flow rate of an air bubble in the inlet tubing was measured. The measurement was
taken for two pressures (range 5-10 cm water) to ensure a linear increase in hydraulic
conductivity with pressure. Measurements were completed in - 2 hours. The hydraulic
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conductivity was calculated by using Darcy's law for one-dimensional flow through
porous media with the following equation:
K = vA c•p At s
AP/ Ax
Where K is the hydraulic conductivity, v is the velocity of the bubble, Acap is the cross-
sectional area of the capillary tube, Atiss is the cross-sectional area of the tissue in the
clamp, AP is the applied pressure drop and Ax is the thickness of the tissue. Experiments
were performed at room temperature.
Cell proliferation assay
1 x 104 mock and MMP-transfected HSTS26T cells were seeded in 96 well plates in
quadruplicate with 100 /l media (DMEM with 10% FBS). After a 48 hr incubation, the
media was replaced with 10 Itl of WST-1 reagent (Roche, Basel, Switzerland) in 90 #l1
serum free DMEM. The cells were incubated for 2 hours at 370C, 5% CO2. The plate was
shaken for 1 minute and the absorbance at 450 nm was measured.
Viral titer
4 x 105 mock and MMP-transfected HSTS26T cells were seeded in 12 well plates. 24
hours later, cells were infected with the oncolytic HSV vector MGH2 at an MOI of 0.1.
After 48 hour incubation, cells and supernatant were collected, subjected to three rounds
of freeze/thaw in a dry ice/ethanol bath and the cell debris pelleted by centrifugation.
Confluent HSTS26T cells in a 96 well plate were infected with serial dilutions of this
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virus prep to titer the virus. EGFP-expressing cells were counted 48 hours after infections
and the viral titer expressed as transducing units.
Sulfated GAG content
Sulfated glycosaminoglycans (GAGs) was measured using the Blyscan assay (Biocolor,
Newtownabbey, Ireland) based on the binding of the cationic dye 1,9-dimethylmethylene
blue (15). Briefly, tumor tissue was harvested and snap frozen in liquid nitrogen and
stored at -800 C. Tissue was solubilized in digest buffer containing 125 pg/ml papain, 0.1
M sodium phosphate, 5 mM Na2EDTA and 5 mM cysteine-HC1, pH 6.0. One milliliter of
buffer was used for 50 mg of tissue. Tissue was incubated in digest buffer for 18 hrs at
60'C. 25 il of solubilized sample was added to 1 ml dye reagent and mixed for 30
minutes at room temperature. The samples were centrifuged at 14,000 x g for 10 minutes
to pellet the precipitated polysaccharide-bound dye. The pellet was solubilized in 1 ml of
dissociation reagent and absorbance of the dye measured at 656 nm. Chondroiton 4-
sulphate was used as a standard.
Results
Development of MMP-1 and MMP-8 expressing tumors
Human soft tissue sarcoma HSTS26T cells were stably transfected with full length
human MMP-1 and MMP-8 via retroviral transduction and tumors were grown
subcutaneously in the flank of SCID mice. A western blot of the tumor lysate showed that
while each MMP is expressed, the majority is in the latent, inactive form (Fig. 5.2A). For
both MMPs, the zymogen retains the propeptide domain and is thus -10 kDa larger than
140
the active form and runs higher on the gel. An in vitro collagenase activity assay was
performed on tissue lysate from mock and MMP-transfected tumors (Fig. 5.2B). The
collagenase activity in both MMP-expressing tumors was not significantly different than
mock-transfected tumors. When the MMP-activating agent trypsin was added, the
activity in the lysates from MMP-expressing tumors increased significantly compared to
both lysate without trypsin and the mock transfected tumor lysate (P < 0.05 for all cases).
These results are consistent with the western blot analysis; they suggest that the MMP-
expressing tumors contain latent collagenases that are not activated in the interstitial
space and that maximal collagenase activity has not been achieved.
One other mechanism that may reduce collagenase activity is the presence of MMP
inhibitors in the tumor. Activity assays were performed to assess the presence of
inhibitors in both the mock and MMP-transfected tumors (Fig. 5.2C). The activity of
corneal collagenase was measured in the presence and absence of 100 /tg of tumor lysate.
Collagenase activity was not reduced significantly compared to the collagenase control
for any of the tumors, with no apparent effect of dose. While this does not rule out that
inhibitors are present, it does suggest that any inhibitors present are already bound to
collagenases in these tumors. In total, these activity assays suggest that activation - rather
than inhibition - limits overall collagenase activity. Interestingly, MMP-1 and -8
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Effect of MMP expression on interstitial collagen
Next we assessed the effect of MMP-l and -8 expression on tumor collagen. While the
activity assays and western blot showed that the majority of the MMPs were not in the
active state, even a small active fraction may have an effect on tumor collagen, especially
with chronic expression throughout the course of tumor development. Several assays
were performed to assess tumor collagen. First, a western blot was performed to






antibody targeted to the N-terminus of the ¼ al fragment of MMP-cleaved collagen type
I was obtained from Eunice Lee (Shriners Hospital for Children, Montreal, Canada). The
specificity of the antibody to MMP-1 and -8 cleaved collagen type I was confirmed by
comparing SDS/PAGE and western blots of MMP-cleaved collagen (Fig. 5.3A). The
antibody is clearly specific for the N-terminal neoepitope of the ¼/4 a chain of collagen I.
Western blot analysis of tumor lysates detected no difference in the presence of this
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Figure 5.3. Analysis of collagen I cleavage in MMP-expressing tumors. (A) Validation
of a polyclonal antibody targeted to the N-terminal neoepitope of the MMP-cleaved ral
chain of collagen type I. SDS/PAGE stained with Coomassie blue (left) and western blots
(right) of intact and MMP-1 and MMP-8 cleaved collagen I. The ac and all chains are
slightly higher than the 112 kDa band of the ladder, while the 3/4 cleavage fragments are
slightly below it. The ¼ cleavage fragments are -30 kDa in size. The antibody appears
specific to the ca ¼ fragment of cleaved collagen I. (B) Western blots of tumor lysate
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In a second assay to assess changes in collagen induced by MMP-1 and MMP-8
expression, tumor sections were immunostained for collagen type I. Analysis was
performed on images of stained tissue sections and the fraction of tissue that was stained
for collagen was compared between tumor types. There was no significant difference in
the fraction between each tumor type (Fig. 5.4A). Finally, in vivo multiphoton imaging of
second harmonic generation (SHG) was performed to determine the amount of collagen
in living tumors. Consistent with the previous results, there was no significant difference
in the total SHG signal between the tumor types (Fig. 5.4B). In total, these results show




from mock and MMP-1 and -8 transfected HSTS26T tumors. A western blot of beta actin









Effect of MMP expression on tumor GAG content
While MMP-1 and -8 expression had no major effect on collagen, this does not rule out
that changes occurred in other ECM components. We next measured the effect of MMP
expression on both nonsulfated GAGs (HA) and sulfated GAGs. HA content was
















Figure 5.4. Interstitial collagen I level in MMP-expressing HSTS26T tumors. (A)
Comparison of the fraction of area containing collagen I immunostaining for mock and
MMP-1 and -8 transfected tumors. Image analysis was performed on maximum intensity
projections of multiphoton image stacks taken for each tumor section. There is no
statistically significant difference between tumor types. (B) Comparison of the average
SHG signal from dorsal chamber tumors. Image stacks 130 #m deep were taken of each
tumor and total SHG signal was quantified. There is no statistically significant difference
between tumor types. Mean values and standard errors shown in both cases.
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biochemically using a 1,9-dimethylmethylene blue dye-binding assay. We found that
there was no difference in HA content between mock and MMP-expressing tumors (Fig.
5.5B). However, MMP-1 and MMP-8 expression caused a significant reduction in
sulfated GAG content (Fig. 5.5A). This is an unexpected result since MMP-1 and -8 have
been traditionally identified as type I collagenases and we found that the overexpressing
tumors showed little collagenase activity. However, it is not entirely surprising since
these MMPs also have various other matrix substrates, the catabolism of which is not






























Effect of MMP expression on interstitial transport
Next we assessed the effect of this change in the tumor matix induced by MMP-1 and -8
expression on interstitial transport. The diffusion coefficient of 1x106 molecular weight
dextran was measured with multiphoton fluorescence recovery after photobleaching for
each tumor type (Fig. 5.6). No difference in the diffusion coefficient was observed
between mock and MMP-transfected tumors. This result is expected, as our labs has
previously shown that there is a strong correlation between diffusion and collagen
content, but not GAG content (5, 6). On the other hand, it has been shown that convective
transport is strongly regulated by the tissue GAG content (16, 17). Thus we also
measured the hydraulic conductivity of these tumors. Indeed, we found that in MMP-1
and -8 expressing tumors, the hydraulic conductivity was more than two-fold greater than
the mock-transfected (Fig. 5.7). It appears that MMP expression can enhance convective
















Effect of MMP expression on oncolytic HSV
Based on these encouraging - albeit unexpected - findings, we next sought to determine
ifMMP-1 and -8 expression could enhance the efficacy ofoncolytic HSV therapy. In
theory, an increase in hydraulic conductivity could enhance the flow of intratumorally
injected HSV particles into the tumor tissue, improving distribution and efficacy. To test
this hypothesis, mock and MMP-expressing HSTS26T tumors were grown
subcutaneously in the leg of SCID mice. For all three groups, tumors were treated with
two intratumor injections of either 2.5 x 106 t.u. of the oncolytic HSV vector MGH2 or
PBS control. Tumor growth in each of the six groups was monitored following treatment
and the time for tumors to grow to ten times the size at treatment was compared (Fig.
5.8). Tumor growth was significantly delayed in the treatment group compared to control
in only MMP-1 and MMP-8 expressing tumors and not in the mock-transfected tumors.
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Figure 5.7. Hydraulic conductivity of MMP-expressing tumors. Mock-transfected and
MMP-expressing HSTS26T tumors were grown subcutaneously and the hydraulic
conductivity of tissue sections measured. Mean values and standard errors shown. MMP-
1 and MMP-8 tumors exhibit a significantly greater hydraulic conductivity compared to
mock (P < 0.05).
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To gain insight into the differential response to MGH2 treatment and to determine if this
effect is indeed transport-related, HSV immunostaining was performed on tumors 7 days
following treatment with a single injection of MGH2. In mock-transfected HSTS26T
cells, HSV particles were present only in the periphery of the tumor. In contrast, for
MMP-1 and MMP-8 expressing tumors, HSV particles were located in both the periphery
and center of the tumor (Fig. 5.9A). The fraction of tumor area containing HSV staining
was quantified (Fig. 5.9B). As expected from the growth delay results, MMP-expressing
tumors had significantly more HSV staining than mock. When the tissue HSV staining
was subdivided into "periphery" and "middle" subfractions, we found that the majority of
the difference was due to the increase in HSV staining in the middle of the MMP-
expressing tumor sections. The lack of HSV staining in the center of the mock-
transfected tumor sections is interesting since MGH2 was injected directly into the center
of the tumors. It appears that in mock-transfected tumors, virus found preferential
pathways through the tumor and distributed outside of the tumor, rather than in the
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Figure 5.8. Effect of MMP expression in HSTS26T tumors on oncolytic HSV-induced
growth delay. (A-C) Mean tumor volume of treated (green) and non-treated (red) mock
transfected (A), MMP-1 expressing (B) and MMP-8 expressing (C) HSTS26T tumors.
(D) Comparison of time for tumors to reach ten times the initial size at treatment. Mean
and standard errors shown. Mock transfected tumors show no significant growth delay
for MGH2-treated tumors. MMP-1 and MMP-8 expressing tumors showed a significant
growth delay between control and MGH2-treated tumors (P < 0.05). Mean values and
standard errors shown in all cases.
center. Thus infection is only observed at the edge of the tissue section. This could occur
with HSTS26T, which has been found to be a very stiff tumor, with high resistance to
fluid flow leading to highly non-uniform distributions of infused agents (18). By reducing
the resistance to fluid flow, MMP-1 and -8 expression has allowed for greater distribution















Figure 5.9. HSV staining of MGH2-treated tumors. (A) Representative images of HSV-1




Effect of MMP expression on cell proliferation and HSV infectivity
Since MMPs can have pleiotropic effects - sometimes playing a role in cell signaling as
well as matrix catabolism - it is important to determine if MMP-l and -8 expression
induced any biological response in these tumors. First we tested whether MMP-1 and
MMP-8 expression affected cell proliferation and tumor growth. Analysis of the rate of
tumor growth for control treated tumors showed that MMP expression did not have a
significant effect (Fig. 5.8A). A WST-1 assay showed that cell proliferation and viability
in vitro are also not affected by MMP-1 or -8 expression (Fig. 5.10A). Next we tested if
the MMP-transfected cells differ from the mock-transfected in either HSV infectivity or
burst size. The viral titer of the three cell lines 48 hours following infection at an MOI of
0.1 was compared. There was no significant difference between mock and MMP-
transfected cells (Fig. 5.10B). These results show that the enhanced response of MMP-l
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and -8 expressing tumors to oncolytic HSV is not due to a modulation in cell viability or
the infectivity of HSV. Rather it appears that MMP expression enhances the therapeutic
effect of oncoltyic HSV by increasing the hydraulic conductivity and improving the























MMP-expressing oncolytic HSV vectors
Finally, in order to apply the matrix-modifying approach in a clinically-relevant manner,
we generated novel oncolytic HSV vectors which express either MMP-l or MMP-8.
While the MMP-expressing tumors are valuable experimental tools, stable transfection of
tumor cells in this manner is obviously not a feasible approach in the clinic. The
alternative is to generate oncolytic HSV vectors which contain expression cassettes for
these MMPs. When tumors are treated with these vectors, MMP-1 or MMP-8 will be
expressed and secreted from infected tumor cells prior to their lysis. We applied the
HSVQuik system developed by Terada et al. (12) to generate these oncolytic vectors. The
three vectors generated (HsvQ1 expressing no transgene, HsvQ1-MMP-1 expressing
MMP-1 and HsvQ1-MMP-8 expressing MMP-8) are similar to MGH2 in that they
contain deletions in both copies of the y34.5 gene and transgene insertion at the UL39
locus. First, we confirmed expression of MMP-l and MMP-8 in cells infected with these
recombinant vectors (Fig. 5.11A). Then we treated wild type HSTS26T tumors with each
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Figure 5.10. Effect of MMP-1 and -8 expression on HSTS26T cell proliferation and
response to MGH2 infection. (A) WST-1 cell proliferation assay performed on mock,
MMP-1 and MMP-8 transfected cells. Cells were allowed to grow for 48 hours following
seeding and the absorbance of 450 nm light was measured following application of WST-
1. There is no significant difference between cell lines. (B) Comparison of the viral titer
48 hours following infection at an MOI of 0.1. There is no significant difference between
cell lines. Mean values and standard errors shown in both cases.
of these three vectors to assess if MMP-expression from infected cells could enhance the
transport of the viral vectors and overall treatment effectiveness. We found that there was
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Figure 5.11. Treatment of HSTS26T tumors with MMP-expressing oncolytic HSV
vectors. (A) Confirmation of MMP expression in infected cells. Vero cells were infected
with either recombinant oncolytic HSV vector HsvQ1 or HsvQ1 variants which express
MMP-1 (HsvQ1-MMP-1) and MMP-8 (HsvQ1-MMP-8). MMP-1 (left) and MMP-8
(right) western blots were performed. Significant amounts of MMP-l and MMP-8 were
observed in HsvQl-MMP-1 and HsvQl-MMP-8 infected cells, respectively, compared to
control. (B-C) Wild type HSTS26T tumors were grown subcutaneously in the leg of
SCID mice and treated with two intratumor injections of either PBS, HsvQ1, HsvQ1-
MMP-1 or HsvQ1-MMP-8. (B) Mean tumor volume of treated and control tumors. (C)
Growth delay induced by oncolytic HSV treatment, given as the time for the tumor to
grow to ten times the size at treatment. There is no significant difference in the growth
delay between HsvQ1 and HsvQ1-MMP-1 or HsvQ1-MMP-8 treated tumors. Mean








Enzyme activity in MMP-expressing tumors
Using multiple methods we have shown that MMP-1 and -8 expression in HSTS26T
tumors does not lead to significant changes in tumor collagen. Inhibition of collagenase
activity by TIMPs has been ruled out as the cause since our activity assay showed no
inhibition of corneal collagenase activity by any of the three tumor lysates. Western blot
analysis shows that only a small proportion of the enzyme is in the active state. When an
activating agent was added to tumor lysates, the activity in these samples increased
significantly. These data suggest that the likely reason why changes in tumor collagen
were not observed is because the secreted enzymes are insufficiently activated. However,
one other possibility is that MMP-1 and -8 are being activated but simply are not
particularly potent collagenases in vivo, at least with respect to the amount of degradation
desired for our application. These MMPs exists in three main structural states: zymogen,
active form and intramolecularly degraded inactive form (19, 20). It may be that the
steady state concentration of active enzyme is low even in the presence of copious
amounts of activating agents, resulting in a faint active enzyme band on western blots and
low "instantaneous" activity in our collagenase assays. Then why did we not observe
changes in tumor collagen? Well, we have been using as a standard for significant
changes in collagen the amount of degradation induced by bacterial collagenase
treatment. However, we have found that bacterial collagenase is a significantly more
effective collagenase than either MMP-1 or MMP-8 both in vitro and in vivo when they
are delivered as recombinant proteins. Bacterial collagenase differs in its collagenolytic
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activity than MMP-1 and -8: it cleaves at multiple sites rather than one and possesses
potent gelatinase activity (21-24). Thus, it is possible that MMP-1 and -8, by themselves,
may not be able to induce similar dramatic changes in tumor fibrillar collagen.
Regardless of whether insufficient activation or lack of potency is the main cause of
limited collagen degradation, collagenolysis can likely be improved by increasing the
proportion of MMP-l and -8 found in the active state. There are several approaches to
accomplish this. An indirect method is to grow MMP-expressing tumors in host tissues
which are more likely to contain proteases which can activate the latent enzymes. Both
MMP-1 and -8 have been successfully used to treat liver fibrosis (25, 26). In these
studies, latent MMP-1 and -8 delivered via adenoviral vectors were activated in the liver
and led to a significant reduction in collagen. This suggests that tumors grown in the liver
may be amenable to treatment with collagenases. A more direct application of this
approach is to combine MMP expression with application of an activating agent. In vitro
studies have identified a host of enzymes and chemicals which can activate MMP-1 and -
8 (27-32). The difficulty with this approach is that these agents can be toxic (e.g.
APMA), require proteolytic activation themselves (e.g. MMP-3) or have ECM substrates,
themselves (e.g. trypsin), which can lead to confounding and unwanted effects. The most
promising approach may be to modify these MMPs genetically. These MMPs have a
unique domain structure which lends them to genetic manipulation to attain constitutively
active forms. The generation of such mutant forms of MMP-1 and -8 is the focus of the
following chapter.
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HSV distribution in MMP-expressing tumors
The observation that HSV vectors showed minimal distribution around the site of
injection in the center of the tumor is not entirely surprising given the low hydraulic
conductivity in these tumors. Netti et al. measured the elastic modulus and hydraulic
conductivity in four tumors and found that HSTS26T was the hardest and had the greatest
resistance to flow (5). Our measurement of the hydraulic conductivity of HSTS26T using
the tissue clamp method concurs with the measurement in that study from confined
compression tests. The extreme stiffness of this tumor likely causes the unique
distribution of injected agents. Boucher et al. found that when they infused Evans blue-
labeled albumin into the center of HSTS26T tumors at a flow rate of 0.05 dl/min, it
distributed asymmetrically from the source and often in necrotic regions (18). Fluid
accumulation was found away from the infusion site - including at the surface of tumors
- with channels of fluid connecting regions of accumulation. Limited necrosis was
observed in the tumors studied in this work, likely because in vitro measurements were
performed on relatively small tumors (100-200 mm3) to match the size at treatment with
oncolytic HSV. However, the pattern of flow of fluid through preferential pathways
rather than bulk flow to the surrounding tissue is consistent with their findings. When the
authors of this study performed similar injections in the colon adenocarcinoma LS 174T,
which has a 5-fold greater hydraulic conductivity than HSTS26T, they found that dye
distributed symmetrically around the infusion needle in the center of the tumor. Thus, our
results suggest that an increase in hydraulic conductivity in this tumor - which is
particularly stiff and resistant to fluid flow - can significantly enhance the delivery of
injected viral vectors.
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What causes this change in hydraulic conductivity? Fluid flow is believed to be regulated
chiefly by the GAG content of the tissue (16, 17). Both Swabb et al. and Levick showed a
strong negative correlation between tissue GAG concentration and hydraulic conductivity
(14, 33). In particular, the non-sulfated GAG HA has been found to be a significant
source of hindrance to fluid flow (34, 35). However, Levick's analysis shows that GAGs
alone - or even GAGs and collagen alone - cannot account for all of the resistivity to
fluid flow in most tissues. When corneal stroma was treated with both trypsin and
hyaluronidase, trypsin caused a greater depletion of sulfated GAGs and greater increase
in hydraulic conductivity (34). Unlike hyaluronidase, trypsin is a protease with broad
substrate specificity that can act on proteoglycan core proteins as well as glycoproteins.
Thus, this study suggests that perhaps GAGs other than HA - the sulfated GAGs - and
other glycoproteins may affect tissue hydraulic conductivity. It is possible that MMP
expression increased hydraulic conductivity by modifying one of these components.
While both MMP-1 and MMP-8 are commonly known as type I collagenases, they have
multiple other ECM substrates (4). Degradation of an alternative substrate - perhaps even
one yet to be identified - may be responsible for the change in hydraulic conductivity that
was observed with the MMP-overexpressing tumors. Both MMP-1 and MMP-8 have
been shown to be able to degrade the proteoglycan aggrecan (36). Aggrecan contains
both chondroiton sulfate and keratin sulfate chains and up to 100 monomers interact with
hyaluronic acid via an N-terminal globular domain (37-39). Cleavage occurs in the
interglobular domain near the HA binding site, releasing the portion of the core protein
that is GAG-bound. Aggrecan is found mainly in cartilage, where its complex with HA
creates a hydrated, space-filling gel that plays a role in cyclical load bearing. While
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aggrecan is not typically found in neoplastic tissue, tumors are often found to have
elevated levels of other chondroiton sulfate proteoglycans (40-42). The likely
proteoglycan found in tumors is versican, which is in the same family of proteoglycans as
aggrecan, has a similar domain structure and binds HA to form aggregates (43). While
versican has yet to be explored as a substrate for MMP-1 or -8, link protein - which
stabilizes the interaction of both aggrecan and versican with HA - has been found to be
cleaved by MMP-1 (44). Furthermore, aggrecanases of the ADAMTS (a disintegrin and
metalloprotease with thrombospondin type 1 motifs) family of proteases have been found
to be able to cleave versican, as well (45-48). These results suggest that degradation of
proteoglycans in the MMP-1 and -8 expressing tumors is possible. However, there are a
host of other candidate ECM proteins whose degradation may lead to alteration of tumor
hydraulic conductivity, since these MMPs have been found to cleave various other
fibrillar collagens (49-52) and glycoproteins (53-56).
The finding that convective transport was enhanced by MMP-l and -8 expression but not
diffusive transport is consistent with the change observed in tumor GAG but not collagen.
We have previously shown that there is a positive correlation between tumor collagen
content and both diffusive hindrance (57, 58) and resistance to flow (59). However,
disruption of tumor GAG with hyaluronidase has been shown to increase hydraulic
conductivity in various tissue (16, 34, 60), but has been found to only slightly affect
diffusive transport, and in the opposite direction (Trevor McKee, personal
communication). Furthermore, Netti et al. measured hydraulic conductivity and the
diffusion coefficient of tracer molecules in a panel of tumors and found that there was no
strong correlation between diffusive and convective transport in a given tumor (5). It is
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becoming increasingly clear that collagen and GAGs play an interconnected role in
regulating interstitial transport and that there are no simple relationships connecting
collagen with diffusion and GAGs with convection.
Implications for tumor therapy
While the novel MMP-expressing oncolytic HSV vectors developed in this study showed
no improvement over the wild type vector, this result is not entirely discouraging and in
fact supports the other findings about the effect of MMP expression on tumor interstitial
transport. Our results suggest that chronic MMP-1 and -8 expression improves the initial
delivery of virus - by enhancing convection into the tissue during intratumor injection -
but would not significantly enhance subsequent propagation, which is affected by
diffusion rather than convection. With the recombinant vectors, MMPs are not expressed
until after the initial infection of tumor cells. Thus, the initial distribution would be
expected to be similar to that of virus injected into the mock-transfected tumors. The
subsequent distribution of progeny virus and therapeutic efficacy would not be enhanced
since MMP expression does not significantly affect diffusion and also because the poor
initial distribution into the periphery of the tumor limits the number of initially infected
cells.
These results point to the importance of initial virus distribution in determining overall
treatment outcome, a phenomenon we and others have previously observed (1, 61).
Therefore, optimizing intratumoral infusion parameters is a promising method to improve
the distribution and efficacy of therapeutics. Bobo et al. have shown that the use of
prolonged infusion can enhance the delivery of macromolecules to the brain, and that the
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distribution can be further improved by increasing the volume of infusion (62). However,
this may not be a viable method for all tumors. For example, this work as well as the
study of Boucher et al. (18) show that certain tumors have a matrix composition and
structure which makes it difficult to achieve adequate convection during infusion. The
findings in this chapter establish a novel technique which may substantially improve the
treatment of such tumors. By modifying the tumor, itself, with matrix degrading
proteases such as MMPs, the distribution of therapeutic agents during infusion may be
enhanced.
Despite this encouraging result, our findings also suggest that there is much room for
improvement. The collagenase activity assays showed that the MMPs expressed in these
tumors were predominantly in the inactive state. Overcoming this activation barrier may
have two positive effects: (1) an increase in collagenase activity which could improve
diffusive transport in the interstitium; (2) enhancement of sulfated GAG depletion which
could further augment convective transport during intratumor infusion. If such techniques
to activate MMPs can be developed, the concept of incorporating matrix proteases into
oncolytic viruses to improve the spread of progeny virus may find greater success than
achieved here. Using genetic modifications to enhance the ability of MMP-1 and -8 to
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Chapter 6: Genetic Modifications to Enhance MMP Activity
170
Introduction
In the previous chapter we found that MMP-l and MMP-8 are not extensively activated
by proteases in the extracellular space of HSTS26T tumor xenografts. Thus, they have
not reached their full potential as enzymes which can degrade interstitial fibrillar collagen
type I and improve the transport characteristics of tumors. Reaching this potential may
require modification of these proteins to tip the balance between active and latent
enzymes in the tumor.
Both MMP-1 and MMP-8 fall into the "simple hemopexin domain" structural class of
MMPs (1). They contain a signal peptide, followed by a propeptide domain, catalytic
domain, hinge region and hemopexin domain. The signal peptide directs the protein to
the enodoplasmic reticulum and allows for secretion into the extracellular space. The
catalytic domain contains the catalytic zinc, which is bound by three His residues (2-4).
The hinge region - whose role is still uncertain - links the catalytic domain to the
hemopexin domain. The C-terminal hemopexin domain is involved in the recognition of
and binding to collagen. Forms of MMP-1 and MMP-8 which lack the hemopexin
domain can cleave gelatin (denatured collagen molecules) and short synthetic peptides
that correspond to the cleavage site in collagen I, but are not active against collagen itself
(5-7). The propeptide domain - which extends from the N-terminus created by the
deletion of the signal peptide to the catalytic domain - has been found to interact with the
catalytic site and keep the full length enzyme latent. A propeptide cysteine residue in the
conserved sequence PRCGVPD is coordinated to the zinc atom in the active site through
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the -SH group (8, 9). Collagenase activity is observed only when the propeptide domain-
catalytic domain interaction is disrupted or the propeptide domain is cleaved off.
Based on the domain structure of MMP-l and MMP-8 and the roles each domain plays,
one obvious method to develop a constitutively active collagenase is to delete the
propeptide domain. This truncated protein would not require activation in the
extracellular space. Here we describe our efforts to create such modified MMPs.
Materials and Methods
Construction of expression vectors and MMP mutants
The cDNA coding for human MMP-1 was purchased from ATCC. The cDNA coding for
human MMP-8 was a gift from David Tarin (University of California, San Diego). To
create an expression vector for the full length enzymes, both MMPs were subcloned into
the vector pEAK13 (Brian Seed, Massachusetts General Hospital). For MMP-1 the
forward primer 5'-CAGCTGGCTAGCTTCCCAGCGACTCTA-3' and reverse primer
5'GTCGACGCTAGCGACTCACACCATGTG-3' were used with SpeI/BglII restriction
digest of the PCR insert and NheI/ BamHI digest of pEAK13. For MMP-8 the forward
primer 5'-CAGCTGGGATCCTTTCCTGTATCTTCT-3' and reverse primer 5'-
TCTAGAGGATCCTCAGCCATATCTACA-3' were used with NheI/BamHI digest of
both the PCR insert and pEAKl3. Both MMP-1 and MMP-8 were inserted in frame with
the signal sequence in the pEAK13 expression vector.
To generate a truncated version of MMP-1, PCR was performed with the new forward
primer 5'-CAGCTGGCTAGCTTTGTCCTCACTGAG-3' and the same reverse primer
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used for full length MMP-1 subcloning. The amplified insert was subcloned into
pEAK13 in frame with the signal sequence. Similarly, to generate a truncated version of
MMP-8, the new forward primer 5'-CAGCTGGGATCCATGTTAACCCCAGGA-3'
was used with the same reverse primer for full length MMP-8 subcloning.
To generate the truncated MMP-1 hinge mutant, a strategy adapted from O'Hare et al
was used (10). The cDNA was modified by PCR in two steps. The forward primer 5'-
GACGATCGCAAAATCCTGTCCAGCCCAGCG'3 was paired with the full length
enzyme reverse primer to generate the C-terminal half of MMP-1 containing the
Ile270OSer mutation. The reverse primer 5'-TTGCGATCGTCCATATAGGGCTTGGAT-
3' was paired with the truncated MMP- forward primer to generate the N-terminal half
of MMP-l containing the Ile259Leu mutation. In both PCR products, two silent
mutations were also introduced in order to generate PvuI restriction enzyme cleavage
sites. The two PCR products were inserted into pEAK13 in a three-way ligation with
SpeI/PvuI and BgllI/PvuI digests of the inserts and NheI/BamHI digest of the vector.
To generate the truncated MMP-8 hinge mutant, the strategy of overlap extension
mutagenesis was employed (11, 12). The forward primer 5'-
GGAGCTTCAAGCAACCCTGCCCAA-3' was paired with the full length enzyme
reverse primer to generate the C-terminal half of MMP-8. The reverse primer 5'-
TTGGGCAGGGTTGCTTGAAGCTCC-3' was paired with the truncated MMP-8
forward primer to generate the N-terminal half Both PCR products contain the
Leu243Ala and Ile248Ala mutations. PCR was performed on these two fragments (which
contain overlapping sequences) to recover the full length product. This PCR product was
173
subsequently subcloned into pEAK13 with SpeI/BgllI digest of the insert and
NheI/BamHI digest of the vector.
Transient and stable cell transfections
293ET and HSTS26T cells were cultured in 6-well plates under standard conditions.
Transient transfections were performed with Lipofectamine 2000 (Invitrogen, Carlsbad,
CA) according to the manufacturer's instructions. To generate stable HSTS26T
transfectants, cells were transfected in 60-mm dishes and passaged at a 1:20 dilution into
fresh growth medium 24 hours after transfection. Twenty four hours after passaging the
media was replaced with fresh media containing 0.5 Ag/mL puromycin. Media with
puromycin was changed every 5 to 6 days. Individual colonies were selected, expanded
and screened.
A retroviral transfection system was also used to generate stable transfectants. The
protocol was adapted from one previously described (13). Briefly, the full length,
truncated and mutated-truncated forms of MMP-1 and MMP-8 were subcloned into
pMSVCneo (Clontech Laboratories, Mountain View, CA) using the pEAK13 vectors as
templates. 80-90% confluent T75 flasks of 293ET packaging cells were transiently
transfected with each MSCV vector (15 Lg) in combination with plasmids expressing
vesicular stomatitis virus glycoprotein (VSVG, 5 jig) and gag/pol (7 jig). After overnight
incubation, the 293ET cells were washed three times with PBS and then 10 mL of fresh
media was added. The following day the conditioned media containing retrovirus was
collected and fresh media added to the flask. The conditioned media was spun down to
remove any cell debris and passed through a 0.45 /M filter (Whatman, Middlesex, UK).
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Subconfluent HSTS26T cells were incubated with the conditioned media containing
retrovirus. The conditioned media from the 293ET packaging cells were collected the
following two days and transduction repeated. Transfected cells were selected by
culturing with media containing neomycin.
Protein isolation
Cells were pelleted by centrifugation and resuspended in 100 /L RIPA buffer. Samples
were kept on ice for 30 minutes and then spun down at 14,000 g for 20 minutes to pellet
the cell debris. The supernatant containing cellular proteins was collected. Protein
concentration was measured using the Bradford assay (BioRad Laboratories, Hercules,
CA) according to the manufacturer's instructions. Pre-diluted BSA (Pierce
Biotechnology, Rockford, IL) was used as a protein standard. Protein samples were either
used immediately in activity assays or western blots, or were frozen down at -800 C.
Activation and inhibition of MMPs
To activate latent MMPs, samples were incubated with p-aminophenylmercuric acetate
(APMA, Sigma, St. Louis, MO). APMA was dissolved in DMSO at a stock concentration
of 20 mM and used to activate MMPs at a final concentration of 2 mM. Samples were
incubated at 37'C for 1 hr and western blot analysis proceeded immediately afterward.
For samples in which activity was assessed, APMA was removed with a centricon filter.
GM6001 (Ryss Lab, Union City, CA) was used to inhibit MMP autoproteolysis in certain
transfections. It was prepared by dissolving in DMSO at a stock concentration of 50 mM.
293ET cells were transfected in 6 well plates. 2.5 hrs after transfection, the media was
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replaced with 2 mL of fresh media containing either 1:1000 DMSO or 1:1000 50 mM
GM6001 (50 /M final concentration). Conditioned media and cells were collected 6
hours later for western blot analysis.
Western blot
Loading buffer containing 0-mercaptoethanol was added to the protein samples and they
were boiled at 1000 C for 5 minutes. Samples were loaded into a 10% Bis-Tris gel
(Invitrogen, Carlsbad, CA) and run at 150V for - 1 hr. The proteins were transferred to a
nitrocellulose membrane in an Invitrogen gel box. The transfer was performed at 30V for
1 hr at room temperature. The membrane was washed with TBST for 10 minutes. The
membrane was placed in 20 mL blocking buffer (TBST with 5% milk) and incubated at
room temperature for 3 hrs with gently shaking. The membrane was incubated with
primary antibody at 40C overnight with gentle shaking. Polyclonal antibodies AB806 and
AB8115 (Millipore, Billerica, MA) were used at a dilution of 1:2,500 for detection of
MMP-1 and MMP-8, respectively. The following day, the membrane was washed 3x for
10 minutes with TBST with vigorous shaking. The membrane was then incubated for 1 hr
at room temperature with an HRP-conjugated secondary antibody (Amersham). The
membrane was washed again with TBST with vigorous shaking and proteins detected
using the ECL or ECL Plus kit (Amersham, Buckinghamshire, UK). For cell lysate
samples, membranes were stripped by incubating with stripping buffer (Pierce
Biotechnology, Rockford, IL) at 370 C and beta actin detected with a polyclonal antibody
(Santa Cruz Biotechnology, Santa Cruz, CA).
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Collagenolytic activity assay
MMP activity was determined using an in vitro collagenolytic activity assay modified
from the method of Johnson-Wint et al. (14, 15). Briefly, type I collagen was purified
from rat tail by solubilization with acetic acid and subsequently acetylated with ['4C]
acetic anhydride. Fibrils were allowed to form from the radiolabeled collagen and were
dried onto wells of a 96-well plate, forming a thin film. Conditioned media samples were
added to wells and incubated at 37oC for 2.5 hours. The supernatants containing soluble
radiolabeled collagen (from cleavage) were transferred to scintillation vials and counted
in a Beckman model LS-3801 scintillation counter. Bacterial collagenase was used as a
control to cleave all the radiolabeled collagen in select wells. One unit of activity
corresponds to degradation of 10% of the collagen in 2.5 hrs at 370 C.
Results
Generation of truncated MMPs
Truncated versions of both MMP-1 and MMP-8 lacking the propeptide domain were
generated as described in Materials and Methods. A schematic diagram of the domain
structure of the wild type enzyme and the truncated mutant is shown in Fig. 6.1. Transient
transfections were performed to generate the enzyme in 293 cells. Cells were also
transfected with the empty vector and with the wild type/full length enzymes as controls.
The 12 hour serum-free conditioned media was collected and western blot performed to
detect the presence of the protein (Fig. 6.2). The truncated forms are expected to be -10
kDa smaller than their full length counterparts (57 vs 47 kDa for MMP-1 and 75 vs 64
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kDa for MMP-8). No active form of the enzyme appears in the truncated MMP
transfection samples. Rather, ~25 kDa proteins were observed. These were believed to be






Figure 6.1. The protein structure of wild type and truncated forms of MMP-1 and -8.
Both MMP-1 and -8 exhibit the MMP domain structure classified as simple hemopexin
domain. The amino-terminal signal sequence (Pre) directs the protein to the endoplasmic
reticulum for secretion into the extracellular space. A propeptide domain (Pro) contains a
thiol group which can interact with the catalytic site Zn, maintaining the enzyme in the
inactive state. A hinge domain (H) connects the catalytic domain with the hemopexin
domain, which is believed to be involved in substrate recognition and binding. In the









Figure 6.2. Development of truncated MMP-1 and MMP-8. Western blots of 12 hr
conditioned media from 293 cells transiently transfected with empty vector, vector
expressing full length MMP and vector expressing truncated MMP, for MMP-1 (A) and
MMP-8 (B). The arrows refer to the expected location of the full length zymogen,
truncated/active enzyme and putative autoproteolytic degradation product. In both cases,
the truncated protein is in the degraded form in the conditioned media.
To confirm that these small proteins are indeed degradation products and that this process
is not simply a phenomenon of these truncated proteins, the full length enzymes were
activated with p-aminophenylmercuric acetate (APMA) and the resultant protein
fragments analyzed by western blot. APMA is commonly used to activate MMPs in vitro
(16). This organomercurial disrupts the interaction between the propeptide and catalytic
domains and activation is achieved via autoproteolytic removal of the propeptide domain.
A 1-hr incubation with 2 mM APMA at 370 C resulted in partial activation of both the




as the presence of significant amounts of the degraded protein fragments are detected.
Thus, the small proteins found with the truncated mutants are indeed degradation
products of the active enzymes, and the process of autoproteolytic degradation appears to




Figure 6.3. Autoproteolysis of activated MMP-1 and MMP-8. (A) MMP-l and (B)
MMP-8 western blots of 12 hr conditioned media of transiently transfected 293 cells. The
right lane is conditioned media from full length MMP transfectants following 1-hr
incubation with the activating agent APMA. The arrows refer to the expected location of
the full length zymogen (top), truncated/active enzyme (middle) and autoproteolytic





Published reports have suggested that the degraded forms of both MMP-1 and MMP-8
lack activity against collagen molecules, although the isolated catalytic domains are still
able to cleave the small peptides mimicking the collagen I cleavage site (5-7). Since these
mutant enzymes are being developed as tools to degrade fibrillar collagen type I in
tumors, we assessed the ability of the various fragments to cleave reconstituted collagen
fibrils. The samples shown in Figs. 6.2 and 6.3 were tested in this collagenolytic activity
assay (Fig. 6.4). As expected, both the truncated and full length samples showed no
activity. Only the full length form incubated with the activating agent APMA could
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Figure 6.4. Collagenase activity of truncated and full length MMP-1. 12-hr conditioned
media of 293 cells transfected with empty vector, truncated MMP-1 and full length
MMP-1 were collected and assayed for collagenolytic activity. The full length MMP-1
sample was also activated by incubation with 2 mM APMA for 1 hr at 37oC. One unit of
activity is defined as the degradation of 10% of the total collagen in each well with 2.5
hrs incubation at 370C. Mean values and standard errors shown. Negligible activity is
T_ `I
observed except in the APMA-activated full length MMP-1 sample.
Inhibition of autoproteolytic degradation with cleavage site mutations
In order to overcome this issue of autodegradation and develop forms of MMP-1 and
MMP-8 that are truly constitutively active, we sought to develop forms of each enzyme
that would be more resistant to autoproteolysis. Previous research had identified the
amino acid sequence in both MMP-1 and MMP-8 that appeared to be the sites of
autodegradation. The putative cleavage site is located in the hinge region of each protein,
which connects the catalytic and hemopexin domains. In these studies site-directed
mutagenesis was used to identify amino acids which affect the rate of autoproteolytic
cleavage. Based on these findings, we chose mutations that appeared to stabilize each
MMP the most and incorporated them into the truncated versions of each protein. The
specific point mutations for each "mutated-truncated" MMP are shown in Fig. 6.5.
Mutated-truncated MMP-1 appeared to be more stable than the truncated form, while
mutated-truncated MMP-8 showed no improvement (Fig. 6.6).
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254 DGIQAIYGRSQNPIGPQTP Wild type MMP-I
DGIQALYGRSQNPSGPQTP MMP-I hinge mutant
240 AIYGLSSNPIQPTGSTPKP Wild type MMP-8
AIYGASSNPAQPTGSTPKP MMP-8 hinge mutant
Figure 6.5. Sequences of wild type and mutant MMP-1 and MMP-8. The sequence
A
Conditioned media Cell Ivsate
B
Conditioned media Cell lysate
Figure 6.6. Development of mutated-truncated MMP-1 and MMP-8. (A) MMP-1 and (B)
MMP-8 western blots of 12 hr conditioned media of transiently transfected 293 cells.
Conditioned media is shown on the left side and cell lysate on the right. Detection of beta
actin in the cell lysates is shown at the bottom. Arrows show the expected location of
bands for full length (high), active (middle) and degraded (low) forms. Mutated-truncated
MMP-1 appears to be more stable than the truncated form. Mutated-truncated MMP-8
shows no improvement in stability compared to full length MMP-8. Wild type enzymes
are secreted in significantly greater amounts that truncated forms. Substantially more








Beyond autoproteolytic degradation, we noted another issue that could have negative
consequences for the use of these altered MMPs in vivo. For identical experimental
conditions (i.e. same expression vector/promoter and transfection conditions)
significantly more wild type enzyme was secreted than truncated and mutated-truncated
forms (Fig. 6.6). Furthermore, much more of the truncated forms of the MMPs were
found in the cell lysate compared to the full length, wild type form. We hypothesized that
intracellular autoproteolytic degradation could reduce the amount of enzyme secreted
from the cell. To test this we transiently transfected 293 cells with both the full length
and truncated MMP-1 constructs in the presence and absence of the MMP inhibitor
GM6001 (17), which can diffuse into cells. Conditioned media and cells were collected
after 6 hours of incubation, a duration that was experimentally determined to be short
enough that secretion of truncated enzyme into the media was not substantial. This early
time point ensures that any change in the level of non-degraded truncated MMP-1 in the
conditioned media will arise from increased secretion of this form, rather than reduced
degradation in the media. We found that in the presence of the inhibitor, the amount of
"active" truncated MMP-1 in both the cell lysate and conditioned media increased (Fig.
6.7). This indicates that intracellular degradation of the protein occurs and contributes to
the reduction in the amount of active protein secreted. However, even in the presence of
the inhibitor, the amount of secreted protein was less than that of the wild type protein in
both the extracellular and intracellular fractions. This suggests that intracellular
degradation is not the only reason for the significantly reduced secretion. Most likely
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Cond media Cell lysate
Figure 6.7. Transfection of 293 cells with full length and truncated forms of MMP-l in
the absence and presence of an MMP inhibitor. The inhibitor reduces intracellular
degradation of the truncated mutant (lane 8 vs lane 6) and increases the amount of active
enzyme secreted into the conditioned media (lane 4 vs lane 2). Significantly less
truncated protein is secreted compared to full length (lane 4 vs lane 3). Significantly more
truncated MMP-1 remains in the cell compared to full length (lane 8 vs lane 7).
Since the kinetics of autoproteolytic degradation and the amount of secreted protein in
these in vitro assays may not accurately reflect what happens in a tumor, the next goal
was to study the effect of these modified MMPs on fibrillar collagen and interstitial
transport in vivo. To do so, HSTS26T human soft tissue sarcoma cells were transfected
with the wild type, truncated and mutated-truncated versions of MMP-l and MMP-8.
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Two separate expression vectors were used: a retroviral vector with a murine stem cell
PCMV LTR promoter and a plasmid expression vector with a CMV promoter. In both
cases negligible amounts of the truncated MMPs relative to wild type were detected by
western blot in all of the clones screened. A representative sample of the clones from
transfection with the plasmid expression vector is shown in Fig. 6.8. The autodegradation
and impaired processing of these mutated forms appear to prevent the secretion of
appreciable amounts of active enzyme in cancer cells. Thus, the generation of
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Figure 6.8. Stable transfection of HSTS26T tumor cells with full length and mutated
forms of MMP-1 and MMP-8. MMP-1 and -8 western blots of conditioned media from
representative clones transfected with either empty vector (con), full length MMP (FL),
truncated MMP (T) or mutated-truncated MMP (MT).While the full length forms are
expressed and secreted, very little truncated and mutated-truncated enzyme is secreted.
Future Directions: Furin-activatable MMPs
One final genetic approach to creating a constitutively active MMP is to enhance its
activation by inserting a furin consensus sequence between the propeptide and catalytic
domains. Furin is a ubiquitously expressed enzyme involved in the secretory pathway of
cells (18). It cleaves proteins containing the consensus sequence at the trans-Golgi. It
plays a role in processing certain cell surface-bound enzymes and has been found to
activate other MMPs (e.g. MMP-11 and MMP-14) (19, 20). We believe that this version
will have advantages over the truncated version for several reasons. First, furin-mediated
activation is a naturally occurring process for several other MMPs, both membrane-
bound and soluble. Second, the insertion of the 10 amino acid consensus sequence will
likely disrupt proper protein folding and processing less than complete removal of the
propeptide domain. And finally, activation by furin cleavage occurs in the trans-Golgi,
providing less time for intracellular autoproteolytic degradation.
A form of MMP-l containing the inserted furin consensus sequence has already been
developed (19). The secretion of what appeared to be the active form was verified, but
detailed analysis of its activity relative to the wild type enzyme had not been performed.
At our urging, the creators of this recombinant enzyme recently performed this analysis
in order to determine the suitability of this mutant construct for degradation of tumor
collagen in vivo. Strangely, the secreted enzyme was dramatically less active against
collagen I than wild type MMP-1. The mechanism of this reduced activity is not yet
known. It is believed that perhaps structural changes induced by the peptide insertion
caused the furin-cleaved propeptide to remain attached to the catalytic domain,
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preserving the enzyme in the inactive state (S. Weiss, personal communication). Thus,
development of furin-activatable forms of MMP-1 and MMP-8 has not been successful
and requires more extensive research.
Discussion
Based on their domain organization, the creation of constitutively active forms of MMP-1
and -8 seemed like a straightforward exercise. In practice, however, it is quite
problematic and our findings highlight the complexity involved in the balance between
active and inactive forms of these enzymes. We found that the truncated forms of each
protein were secreted in much smaller quantities than the wild type enzymes, with greater
amounts remaining inside the cell. This may be due to improper protein folding or some
other type of impaired processing. While these truncated forms were not overtly harmful
to cells (i.e. no massive cell death of transfected cells was observed in culture), their
toxicity has not been ruled out. In addition, the truncated mutants were also found to go
through rapid inactivating autoproteolysis both extracellularly and intracellularly.
These observations support the idea that the steady state concentration of active MMPs -
and by extension the level of collagenase activity -is tightly regulated in tumors. We
have documented in the previous chapter that even when copious amounts of MMP-l and
-8 are expressed in a tumor, limited amounts are converted to the active form. It has been
shown in vitro that activation of these MMPs can be a multi-step process and that various
serine proteases and MMPs (MMP-2, -3, -7, -10, -11) may be part of the process (21-28).
That each of these MMPs requires activation, itself, suggests that MMP-1 and -8
activation is a highly controlled event that occurs only when collagenase activity is
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needed. Once activated, MMP-1 and -8 can rapidly break down into smaller forms. In
contrast to the activation process, this autoproteolysis is not well studied beyond several
papers that have identified the putative cleavage sites for each MMP (6, 10, 12). While
for our purposes this autoproteolysis can be considered an inactivating cleavage (since
type I collagenase activity is lost), this may not be the only, or true, role in vivo. Isolated
catalytic domains have been found to retain their activity against certain substrates (5-7),
so removal of the hemopexin domain may serve a specific biological role. Alternatively,
autoproteolysis may be a built-in regulatory mechanism to prevent an overabundance of
collagenase activity, which may be harmful in many tissues. In any event, maintaining
high levels of active (i.e. propeptide-free) MMP-1 and -8 in the tumor may be difficult to
achieve.
So what does this mean for engineering constitutively active forms of these collagenases?
There are several possible routes going forward. First, a greater understanding of the
activation processes of these two collagenases is needed, particularly if a rational
approach to protein engineering is taken. While much research has gone into
understanding the activation process of MMP-l and -8 in vitro, the actual method of
activation in vivo is still unknown. Identifying the proteases responsible for activation in
vivo and elucidating the mechanism would help us understand how best to approach the
engineering of these MMPs. Perhaps even co-transfecting MMP-1 or -8 with such an
activating agent may be an effective approach.
A second method to improve activation is to use targeted mutation of the propeptide
domain to disrupt the inactivating interaction it has with the catalytic site Zn. Studies
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which have identified the amino acids in the propeptide domain responsible for the
interaction provide preliminary targets for such mutations (9). These mutations would
likely disrupt proper protein folding and intracellular processing less than truncation of
the enzyme, and thus may hold greater potential. Finally, the method of proteolytic
activation via furin-mediated cleavage of the propeptide domain still holds hope. Further
research should provide insight into why limited activity was observed and how this can
be improved. We should also note that the recovery of full collagenase activity relative to
the activated wild type enzyme is not a requirement. Collagenase activity is a function of
both the inherent activity of the enzyme and also its concentration. Thus, an engineered
form of MMP-1 or -8 that has reduced activity may still be advantageous if greater
amounts are present in the tumor compared with the wild type enzyme, which is activated
in low proportions.
Regardless of how activation of these MMPs is improved, one limiting factor may be
autoproteolytic inactivation. Targeted mutations still provide the best approach to limit
this process. As mentioned previously, autoproteolysis has not been extensively studied.
The stabilizing mutations made in this work were motivated by this existing work and are
likely suboptimal. Further research should identify the proper sets of mutations that
reduce autodegradation while maintaining collagenase activity.
Lastly, an alternative to protein engineering by rational design is the method of directed
evolution. In this approach, a protein is altered at the genetic level and screened for
advantageous characteristics (29). Essentially the process of Darwinian evolution is
carried out in the test tube with the selective pressure applied by the scientist. Directed
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evolution has been used in such applications as enhancing the activity of enzymes (30)
and altering the binding characteristics of proteins (31). The ability to develop robust,
high-throughput screens is critical and will be the limiting step with MMP engineering. If
screens can be developed for both enzyme stability and collagenase activity, this may be
the most effective way to engineer a constitutively active collagenase.
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Interstitial collagen type I has previously been shown to be the primary source of
diffusive hindrance in tumors (1-4). Interestingly, Pluen et al. found that this hindered
diffusion became increasingly more dramatic as the size of the macromolecule being
probed rose (4). Based on this result, we hypothesized that the effectiveness of most
novel cancer therapeutics - such as antibodies and liposomal and viral vectors - could be
significantly impaired due to limited distribution in tumors resulting from their large size.
The first goal of this thesis was to confirm this theory. The second goal was to answer the
following question: can we do anything about this in a clinical setting?
We first addressed the issue of impaired therapeutic efficacy with a mathematical model.
A ID reaction-diffusion model was developed to determine the distribution of a specific
therapeutic, an HSV vector, in a solid tumor. While the model did not explicitly consider
collagen, its effect was incorporated in the diffusion of the viral particles. The model
predicted that HSV vectors would spread only minimally from the injection site
following intratumor infusion. Hindered diffusion and rapid binding were responsible for
this. Importantly, the model predicted that an improvement in diffusion from modulation
of tumor collagen could enhance vector distribution several fold.
These intriguing findings were supported by our experimental results. In vivo imaging of
intratumorally injected HSV vectors showed that their distribution was limited by the
collagen in tumors. The effect appeared to be size dependent, as smaller macromolecules
distributed more uniformly in the tumors. Furthermore, the collagen network limited the
propagation, and thus efficacy, ofoncolytic HSV vectors. These images showed, for the
first time, the direct effect tumor collagen can have in limiting the distribution and
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efficacy of a cancer therapeutic. The second main finding from this study was that
collagen degradation with bacterial collagenase could be used to enhance vector transport
and efficacy. Thus, these results provided proof of principle that the technique of tumor
collagen degradation for enhanced interstitial transport could be used to positively
influence treatment outcome.
However, in order for this concept to advance to the clinic, a human, rather than bacterial,
enzyme needs to be used. MMP-1 and MMP-8 were identified as two potential human
enzymes that could be used in replacement of bacterial collagenase. Unfortunately, our
studies with recombinant MMPs showed that these enzymes are significantly less potent
than their bacterial counterpart. The enhancement of interstitial transport and efficacy of
oncolytic HSV found with bacterial collagenase was not duplicated by either MMP. It
was concluded that in order for these enzymes to effect the changes in collagen and
diffusion necessary to enhance therapeutic efficacy, the dose needed to be increased
substantially.
Genetic delivery of MMPs offered a potential solution to this problem: tumor cells would
be converted to factories producing and secreting these human collagenases. However,
while copious amount of these MMPs were generated and secreted, another problem
arose. These enzymes were insufficiently activated in the extracellular space and thus no
changes in collagen and diffusion were observed. The mechanism of activation of these
MMPs in physiological settings is still unknown. However, in vitro studies suggest that
the mechanism may be quite complex and tightly regulated, as many other MMPs, which
themselves require activation, can cleave MMP-1 and -8 in the propeptide domain (5).
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Thus, the observation that only a small proportion of the MMPs were activated is not
entirely surprising, especially considering the large amount of protein being secreted in
this overexpression model. On the other hand, this result could hardly have been
predicted. In their only other use as enzymes to degrade collagen in vivo, both MMP-1
and MMP-8 were found to be activated in the tissue to which they were delivered (6, 7).
Based on the domain organization of these two enzymes, we proposed a genetic method
of bypassing this activation barrier: deletion of the inactivating propeptide domain.
However, this method of generating constitutively active MMPs was hampered by two
phenomena. First, the truncated/active form of both enzymes went through inactivating
autoproteolysis, both intracellularly and extracellularly. Second, impaired intracellular
processing - possibly from improper protein folding - significantly reduced the amount
of enzyme secreted. In combination, these two effects limited the gains we sought from
deleting the propeptide. Our attempts to reduce autoproteolytic degradation with
stabilizing mutations were unsuccessful. It appears that our understanding of the
autoproteolytic cleavage of MMPs is still in the nascent stages and more research is
needed to effectively block this process.
One intruiging and unexpected result came from our analysis of the MMP-expressing
tumors. While collagen and diffusion were not affected, MMP-l and -8 expression
reduced the sulfated GAG content in tumors and increased tumor hydraulic conductivity.
This led to a significant improvement in the efficacy of an oncolytic HSV vector. This
finding has several important implications. First, it highlights the significance of initial
intratumoral distribution in regulating the overall efficacy ofoncolytic HSV therapy. It
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echoes the findings from our modeling work (Chapter 2) and the bacterial collagenase
study (Chapter 3). This thesis has clearly shown that the physicochemical properties of
HSV and the tumor extracellular matrix combine to severely limit the intratumor
distribution of infused particles. Second, this finding has identified a novel approach to
improve the efficacy of oncolytic viral treatment: enhancing convection during
intratumoral infusion by modifying the tumor matrix with MMPs. By using both bacterial
collagenase to degrade fibrillar collagen and MMPs to deplete tumor sulfated GAGs, this
thesis has highlighted the significant impact that an improved initial viral distribution can
have on the therapeutic outcome of oncolytic viral therapy. However, this work also
emphasizes the pleiotropic nature and complexity of the MMP family of enzymes. Since
they have a host of matrix substrates, it may be difficult to use MMPs to specifically
degrade a single matrix component. Care must be taken in their use since it is likely that
unintended effects will arise.
The use of MMP-1 and -8 to modulate sulfated GAGs and hydraulic conductivity is an
exciting new approach which has the potential to improve the treatment of tumors.
However, oncolytic viral therapy would be further enhanced if this approach could be
combined with a method which improves diffusive transport in tumors. Enhanced
convection would improve the initial viral distribution, while increased diffusion would
allow progeny virus to spread more broadly throughout the tumor. While our efforts to
improve diffusion through collagen degradation were not entirely successful, they
provide valuable lessons and delineate several options going forward. First, our results
have identified several limiting steps in achieving sustained collagenase activity with
MMPs and points to several steps necessary to engineer more efficient enzymes. Clearly,
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a greater understanding is needed in two key areas: the activation and degradation of
MMPs. Knowledge of which proteases activate these two MMPs in physiological settings
would open up the possibility of co-delivery of a set of enzymes to overcome the hurdle
of extracellular activation. While we showed that simple deletion of the propeptide
domain leads to problems in intracellular processing, mutations in the propeptide domain
(to make it more susceptible to cleavage or less prone to interaction with the catalytic
site) or the insertion of a different cleavage site (such as one that leads to intracellular
activation by furin) are still viable options. As for autoproteolytic degradation, a more
thorough analysis of the hinge region would allow us to better stabilize these enzymes
with mutations. A second option is to apply these MMPs to the treatment of different -
more responsive - tumors, rather than modify them to improve their activity in all
tumors. Both MMPs have been shown to be activated in the liver (6, 7). Thus, perhaps
only certain tumors - those growing in a host site that contains the proper factors for
MMP activation - can be treated with this approach. Recently, Cheng et al. incorporated
MMP-8 into a non-replicating adenoviral vector (8). Infection of human lung cancer cells
led to the production of the active form of the protein and the treatment of lung
xenografts reduced the amount of tumor collagen and enhanced the efficacy ofoncolytic
adenoviral therpay. This further suggests that MMP activation is dependent on the tumor
type. Third, our findings may suggest that MMP-1 and -8 are more effective as
modulators of tumor sulfate GAGs and that other agents must be identified to modulate
collagen. Within the MMP family, MMP-14 - which has unique properties like an
intracellular activation mechanism and potential resistance to inhibitors as a membrane-
bound protein (9, 10) - may be better suited as a tumor collagenase. Outside of the MMP
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family of enzymes, cathepsin K may also be an ideal candidate since its acidic pH
activity dependence makes it "targeted" to tumors (which generally have low pH) and it
has not been linked to tumor cell invasion or metastasis. While it was not a potent
collagenase in our in vitro assays, these studies were performed with conditioned media
samples which may have promoted degradation and inhibition. More success may be
found by applying recombinant cathepsin K directly to tumors. In addition, there are
alternative methods to modulate tumor collagen that do not involve the direct use of
collagenases at all. Upstream effectors may be identified which can initiate the entire
expression and processing cascade that is needed to degrade collagen in vivo. This would
bypass the need to develop methods to activate and stabilize the enzymes. Another
approach is to focus on inhibiting collagen deposition, perhaps by blocking TGF-0,
which has been associated with collagen production in tumor fibroblasts (11, 12).
Regardless of which path is taken, this thesis serves as a necessary first attempt to
develop clinically relevant techniques to overcome the barrier to interstitial transport
posed by collagen and sulfated GAGs. It has exposed the difficulties and limitations in
this technique and has identified critical processes that need to be addressed in future
attempts. The negative effect of the tumor ECM on therapeutic delivery and efficacy has
garnered very little attention despite its substantial potency and its broad applicability
among both tumors and therapeutics. We hope that in some small measure this work
shines light on this problem and provides insight into how to overcome it.
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Appendix: Treatment of Liver Tumors
Previous studies have shown that MMP-1 and MMP-8 can be used to treat liver fibrosis
(1, 2). Replication deficient adenoviral vectors were used to genetically deliver the full
length enzymes. While neither MMP was activated in vitro when expressed in liver cells,
both were activated in the extracellular space of the liver in vivo. In both cases, the
amount of collagen in the liver was markedly reduced. These findings led us to
hypothesize that perhaps the activation of these MMPs is dependent on the tumor host
site, with the liver being particularly amenable. In support of this hypothesis, various
proteases have shown the ability to activate (or partially activate) these MMPs in vitro,
and the presence and amount of these proteases - as with many proteins - likely varies by
organ site. To test this hypothesis we performed the following preliminary experiments.
We first tested whether MMPs expressed in tumors would be differentially activated
depending on the site of tumor implantation. MMP-1 and MMP-8 overexpressing
HSTS26T cells (developed in Chapter 5) were implanted in the liver of SCID mice by
direct injection of-5x1l 05 cells into a single lobe. Tumors were also grown
subcutaneously in the leg, a site in which we previously observed limited MMP
activation (Chapter 5, Fig. 5.2A). Mock-transfected tumors were grown in both sites as a
control. After 3-4 weeks, tumors were harvested and western blot performed on the tumor
lysate to determine the levels of active and latent MMPs. For MMP-1, the western blot
shows that for tumors grown in both the liver and subcutaneously, enzyme is primarily in
the latent form (Appendix Fig. 1A). In contrast, MMP-8 was found to be primarily in the
active form in the liver, but in the latent form in subcutaneous tumors (Appendix Fig.
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IB). For both tumor sites, low background expression of each MMP was observed. Thus,













Appendix Figure 1. Expression of MMP-1 and MMP-8 in subcutaneous and liver
tumors. (A) MMP-1 and (B) MMP-8 overexpressing HSTS26T cells were implanted in
the subcutaneous space or in the liver of SCID mice. Western blot was performed on
tumor lysates. The location of bands corresponding to the latent and active forms is
denoted by arrows. Beta actin western blots are shown at the bottom for control. There
is low background expression of both MMPs in mock-transfected tumors in both sites.
While MMP-1 is found predominantly in the latent form in both sites, MMP-8 is found
in the latent form in subcutaneous tumors but in the active form in liver tumors.
Based on these encouraging findings, we decided to test whether tumors grown in the
liver would respond better to treatment with MMP-expressing oncolytic HSV vectors.
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We hypothesized that virus expressing MMP-8 would better spread through the tumor
and control its growth. We performed a tumor treatment experiment similar to that
performed with subcutaneous tumors (Chapter 5, Fig. 5.12). In that previous experiment
we observed no difference in the response to MMP-expressing oncolytic viruses. Here,
wild type HSTS26T cells were first stably transfected with Gaussia luciferase via
lentiviral vectors (gift from Bakhos Tannous, Massachusetts General Hospital). Tumors
were grown in the liver as before. Tumor load was monitored by obtaining 5 tl of blood
from each mouse, adding the luciferase substrate coelenterazine and measuring the
bioluminescence signal. This bioluminescence signal has been found to correlate well
with the tumor load (Xandra Breakefield, personal communication), and provided us with
a method to monitor tumor growth without performing invasive surgery multiple times.
At an appropriate size, tumors were treated with a single intratumor injection of PBS or
2.5 x 106 t.u. of HsvQ-1, HsvQ1-MMP-1 or HsvQ1-MMP-8. Tumor load was monitored
after treatment.
We found that there was no difference in the mean tumor growth rate between treatment
groups (Appendix Fig. 2). There was also no difference between any of the treatment
groups and the control. This latter result suggests that tumors need to be treated with a
higher dose, multiple doses or at a smaller size in order to see a response to the oncolytic
virus. We also observed that tumors grew quite heterogeneously. In some cases, tumors
grew in the middle of the lobe of the liver. In other cases, tumors grew at the edge and
often spread to the abdominal cavity. There were also instances of tumors growing in
both the liver and abdominal cavity in the same mouse. Leakage of tumor cells from the
liver during implantation was observed and likely contributed to this pattern of growth.
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Approximately 1/3 of tumors had significant regions of necrotic tissue at the time of
treatment, although tumors were still relatively small in size. Furthermore, nearly ¼ of
the mice became sick, a condition that did not correlate with tumor size or treatment with
virus. The causes of the unusual behavior are not known. However, to obtain more
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Appendix Figure 2. Treatment of liver tumors with MMP-expressing oncolytic HSV
vectors. Tumors were grown in the liver and treated with a single injection of PBS
control or 2.5 x 106 t.u. of HsvQ-1, HsvQ1-MMP-1 or HsvQ1-MMP-8. Tumor size was
monitored by addition of luciferase substrate and measurement of bioluminescence.
Tumor size is given as bioluminescence signal in arbitrary units. (A-D) Individual
growth curves for control (A), HsvQ1 treated (B), HsvQ1-MMP-1 treated (C) and
HsvQ1-MMP-8 treated (D) tumors. (E) Mean tumor size and standard errors for each
treatment group. Tumors were treated at a bioluminescence signal of 430 ± 216 (mean ±
SD). No significant difference in tumor growth was observed.
In conclusion, no difference was observed in the efficacy ofoncolytic HSV treatment of
liver tumors with MMP-1 or MMP-8 expression. Substantial improvements to both the
experimental model and treatment parameters are needed to definitively assess the
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relative effectiveness of the oncolytic vectors in liver tumors. Furthermore, the
preliminary results with MMP-1 and MMP-8 expression in liver tumors (Fig. 1) should
be confirmed by both western blot and collagenase activity assays and the effect on tumor
collagen should be determined.
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